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Poxviruses are large double-stranded DNA viruses with a broad host range and 
worldwide distribution.  The most infamous poxvirus is Variola virus, the causative agent of 
smallpox, which caused over 500 million deaths in the twentieth century before it was declared 
eradicated in 1980 by the World Health Organization.  Nevertheless, more than 25 years after its 
eradication from nature, smallpox remains a threat, as there is now concern for its use in an act of 
bioterrorism.  Other poxviruses have emerged in recent years.  In 2003, there was a monkeypox 
outbreak in the United States, with nearly 80 cases.  This disease is similar to smallpox, but can 
be spread not only from human to human, but also from animal to human, which emphasizes the 
fact that many poxviruses are a zoonotic threat.  The current poxvirus vaccine (Vaccinia virus, 
VACV), while highly effective, is unsafe and its use is contraindicated for an estimated 25% of
the population due to its virulence.  The virulence of VACV is attributed to the production of 
numerous proteins that function to evade the host immune response, including inhibitors of 
interferons, regulators of apoptosis, and cytokine receptor homologs.  Despite the large amount 
of work that has been done to characterize poxvirus virulence mechanisms, there are more than 
25 highly conserved genes that remain uncharacterized.  The poxvirus A35R gene is highly 
conserved in all sequenced mammalian tropic poxviruses and has little similarity to any non-pox 
protein, suggesting an important and novel function.  The A35 protein was not required for viral 
replication in eight cell lines from various hosts, but removal of A35 from the viral genome 
resulted in a 1000-fold decrease in virulence in the mouse model.  We therefore hypothesized 
that the poxvirus A35 gene product promotes virulence by affecting viral replication in certain 
cell types in vivo or by regulating aspects of the host adaptive immune response.  We show that 
A35 is not required for viral replication in various cell types from six different mammalian hosts 
and also in mouse tissues early after infection.  Using a model major histocompatibility complex 
(MHC) class II-restricted antigen presentation system, we have shown that VACV and A35 
inhibit the amount of numerous cytokines that are produced from both the T cell and the antigen 
presenting cell (APC) as a result of specific antigen presentation, including IL-2 and nitric oxide.  
Further data implicated the APC as the viral target, as the T cells used in the assays were 
unaffected by VACV and A35.  The A35 protein did not induce apoptosis of the APC or affect 
antigen-independent NO production.  Furthermore, A35 localized to the endosomal 
compartments of the APC and decreased MHC class II expression and the amount of peptide 
presented in the cleft of MHC class II molecules.  To determine if A35 would decrease the host 
adaptive immune response, mice were vaccinated with 500 plaque forming units (pfu) of either 
VACV (Western Reserve strain, WR) or A35Δ.  Our data indicate that A35 decreased VACV- 
specific immune response including interferon- (IFN)-γ production, cytotoxic T lymphocyte 
(CTL) killing, serum antibody, and neutralizing antibody.  The decreased immune response was 
shown to be important as it resulted in increased viral replication in target organs.  The A35Δ 
virus was also an effective vaccine, as it protected mice as well as WR from a lethal challenge.  
We also made a recombinant A35 deletion mutant virus in the Modified Vaccinia Ankara 
(MVA) replication-deficient vaccine strain, which has been shown to be safe when used in 
immunocompromised individuals.  Results with MVA were similar to studies performed with 
WR: A35 was not required for virus replication and decreased VACV-specific immune 
responses.  Furthermore, the MVA35Δ vaccine protected mice as well as MVA from a lethal 
respiratory challenge.  Our data expands the knowledge of what is known regarding poxvirus 
virulence mechanisms and is applicable to the development of safer and highly immunogenic 
vaccines.  Since poxviruses are now being used widely as a platform for a number of vaccines 
for various diseases, including human immunodeficiency virus (HIV) and cancer, our work with 
A35 is broadly applicable to vaccine development.     
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CHAPTER 1: REVIEW OF THE LITERATURE 
 
Poxviruses 
 
General Characteristics and Taxonomy   
The Poxviridae are a family of large, enveloped, double-stranded DNA (dsDNA) viruses 
that range in size from 130-300 kilobases (kb) (141).  Unlike all other DNA viruses, poxviruses 
have the unique ability to replicate in the cytoplasm of their host, rather than in the nucleus.  
Poxviruses have worldwide distribution and a broad host range, infecting both insects 
(Subfamily Entomopoxvirinae) and vertebrates (Subfamily Chordopoxvirinae).  Included in the 
vertebrate-infecting subfamily Chordopoxvirinae are the following genera: Orthopoxvirus, 
Parapoxvirus, Avipoxvirus, Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus, and 
Yatapoxvirus.  The focus of this literature review will be the orthopoxviruses, as these are the 
most significant to human health.  Virus species that are included in this genus are Variola virus 
(VARV), Ectromelia virus (mousepox), Monkeypox, Cowpox, and the prototypical poxvirus 
Vaccinia virus (VACV).  These virus species are highly related, and vaccination or infection 
with one confers immunity to all others.  Parapoxviruses, yatapoxviruses, and 
molluscipoxviruses can also infect humans, and will be mentioned briefly. 
Replication Cycle 
 Poxviruses have a complicated replication cycle that occurs exclusively in the cytoplasm 
of the host cell.  Thus, upon entry into a host cell, the virion is equipped with the enzymes that 
are necessary to initiate the transcription of genes required for viral DNA replication (141).  
Virus entry has been shown to be mediated by the viral envelope protein A27, which attaches to 
the cellular surface proteins heparin and heparin sulfate (183).  The expression of poxvirus genes 
is temporally regulated, with early, intermediate, and late gene expression (23).  Once inside the 
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host cell, the virion core begins to transcribe early mRNA, which will be translated into proteins 
that are needed for DNA replication and intermediate transcription.  Also synthesized are 
proteins that function in evading the host immune system, which will be discussed later.  
Uncoating of the core results in the initiation of DNA replication, followed by intermediate 
transcription from the newly synthesized DNA.  Finally, late transcription occurs, producing 
early transcription factors and structural proteins.  These, along with viral DNA, form the newly 
assembled virions (141).    
 Virion assembly occurs in areas of the cytoplasm called virus factories.  Assembly begins 
with the formation of crescent-shaped membrane structures, followed by the packaging of DNA 
to form immature virions (IV).  The IV matures via proteolysis to form the intracellular mature 
virus (IMV), which then undergoes a membrane wrapping event and acquires two additional 
membranes from the trans-golgi, forming the intracellular enveloped virus (IEV) (77, 141, 178).  
The IEV then fuses out from the cell, losing its outermost membrane and forming the 
extracellular enveloped virus (EEV) (78, 172).  Both the IMV and the EEV are infectious forms 
of the virus.  The IMV is released from dying or lysed cells, is extremely stable and thought to be 
the form of virus responsible for transmission from host-to-host.  The IMV can enter the cell by 
either fusion with the plasma membrane (28) or by endosomal entry (215).  The EEV, containing 
one additional membrane compared to IMV, is also infectious and is believed to be the form that 
mediates spread of infection in the host (141).   
Smallpox 
 The most infamous orthopoxvirus is Variola virus (VARV), the causative agent of 
smallpox.  VARV has a 30-40% fatality rate and was responsible for nearly 500 million deaths in 
the 20th century alone before its eradication from nature in the late 1970’s (124).  The eradication 
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of smallpox was due to a successful vaccination campaign involving the related poxvirus, 
Vaccinia virus (VACV).  Smallpox is an exclusively human disease and was able to be 
successfully eradicated due to the fact that no animal reservoir existed, which is not the case with 
most other poxviruses.  Routine poxvirus vaccination in the United States stopped in the early 
1970’s due to high complication rates.  The last natural case of smallpox occurred in Somalia in 
1977, and smallpox was declared eradicated by the World Health Organization in 1980 (124).  
Two official stockpiles of VARV exist in the world, but there are fears that other unknown 
stockpiles may exist and be used in an act of bioterrorism against the United States.  Such release 
of VARV would be devastating, as the current population is largely unvaccinated and would thus 
be susceptible to infection.   
Emerging Poxviruses 
    Since the discontinuation of vaccination programs, the incidence of zoonotic 
orthopoxvirus infections has increased throughout the world.  In South America, a wild VACV, 
known as Cantagalo virus, has infected cattle on over 70 farms and caused disseminated rash in 
humans (45).  The virus is thought to have been transmitted to domestic cattle, where it persisted 
and mutations occurred, and then transmitted back to susceptible humans (45).  There is also 
concern that Cantagalo is rapidly spreading throughout Brazil (135).   
Buffalopox, a close relative of VACV, can infect buffaloes and humans and has been 
associated with numerous outbreaks in India (100, 227).  Buffalopox can cause lesions on the 
teats and udders of both buffalo and cows, which can then transmit the virus to the hands of 
humans.  A hospital outbreak of buffalopox caused by contaminated first aid supplies was 
recently reported at a burn center in Pakistan (228).  Of particular concern is the evidence that 
suggests that buffalopox can also spread from human to human (100).   
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Outbreaks of cowpox have been reported in primate colonies in Europe (129, 132).  The 
outbreaks caused widespread sickness and mortality, raising concerns about the evolution of 
cowpox into a significant primate pathogen.  It was shown that rats captured at the sanctuary 
were positive for infection and were most likely the source of the outbreak.  Human outbreaks of 
cowpox are mostly associated with contact with infected cats (10), and there is evidence for 
human to human spread (118).        
The most dangerous poxvirus that infects humans is monkeypox virus.  This virus causes 
a smallpox-like illness with a 10% fatality rate (63), is commonly carried by African rodents, and 
is endemic to equatorial Africa (47).  In 2003 there was an outbreak of monkeypox in the United 
States associated with the importation of African rodents.  This outbreak caused more than 80 
human infections, but since this was a low virulence strain, no fatalities occurred (34).   
Orthopoxvirus is not the only poxvirus genus with members that cause human disease.  
Tanapox, a member of the genus Yatapoxvirus, is endemic to equatorial Africa, infects primates 
and has been diagnosed in Europe and the United States in recent years (52, 198).  Molluscum 
contagiosum virus, the sole member of the genus Molluscipoxvirus, occurs commonly (and 
exclusively) in humans (39% of a population over 50 years of age tested seropositive in 
Australia) (101) and accounts for approximately 300,000 doctor visits each year in the United 
States (140).  Molluscum causes groups of wart like lesions, is common in children and acquired 
immune deficiency syndrome (AIDS) patients, and is now emerging as a sexually transmitted 
disease.  Members of the genus Parapoxvirus can cause disease in humans, including orf virus 
and pseudocowpoxvirus (137, 168), and these infections are mostly transmitted from sheep, 
goats, or cattle.  
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Poxvirus Vaccines 
Overview and Vaccine-Related Complications 
 Smallpox was eradicated from the world through vaccination using a related virus, 
VACV.  This is a live virus vaccine that is given in the upper arm using a technique called 
scarification.  A “take” is indicated by the presence of a pustule at the vaccination site (85).  The 
pustule will eventually form a scab and fall off.  Vaccine recipients will then have immunity to 
not only smallpox, but to all other related orthopoxviruses.   
Although highly effective, vaccination with VACV was discontinued for the general 
public due to a high rate of adverse events.  Disseminated, or generalized, vaccinia develops as a 
vesicular rash in otherwise healthy people (114).  Eczema vaccinatum can occur in individuals 
with atopic dermatitis or other inflammatory skin conditions, and thus these individuals or their 
contacts should not be vaccinated with live VACV.  Recently, a 2-year old child developed 
eczema vaccinatum and became extremely ill after contact with his father who had received the 
smallpox vaccine because of his military service (111).  Progressive vaccinia occurs in those 
with compromised immune systems, is characterized by a progressive necrosis at the vaccination 
site, and is often fatal (20).  Also associated with vaccination are postvaccination encephalitis 
and myopericaditis.  Indeed, a recent vaccine trial was cancelled due to the increased incidence 
of heart complications (7, 60, 211).  It has been estimated that vaccination with VACV is 
contraindicated for 25% of the population (96), including those with inflammatory skin 
conditions, immunodeficiency, or heart disease, and also for any of their close contacts due to the 
potential for accidental infection of household members.  Thus, VACV maintains significant 
virulence in the human population and mechanisms that contribute to its virulence are of interest.  
 6  
In addition, in the face of emerging disease and bioterrorism, there is a need for a safer poxvirus 
vaccine that can be used in the general public.        
New Generation Vaccines    
 Many strategies are being used to reduce the risks associated with vaccination without 
decreasing either the immunogenicity or efficacy of the vaccine.  The first is the sequential 
passage of virulent wild type VACV in the tissue culture cells of a non-traditional host.  During 
these passages, the properties of the virulent VACV change, resulting in an attenuated virus.  
Modified Vaccinia Ankara (MVA) is an attenuated virus strain that resulted from over 570 serial 
passages of wild type VACV Ankara strain in chicken embryo fibroblasts (CEF).  During this 
time, six major deletions of the genome occurred, totaling approximately 25 kb of DNA (136, 
138), and the virus lost the ability to replicate in most mammalian cells (17).  The avirulence of 
MVA in mammals is attributed to the deletion of numerous genes, including the K1L host range 
gene, and genes for the soluble receptors for both type I and type II interferons (IFN) and tumor 
necrosis factor (TNF) (17).  MVA is able to undergo all steps of DNA replication, and all early, 
intermediate, and late viral proteins are synthesized (98, 204), but morphogenesis stops at the 
formation of immature virions.  This is important, since the production of late viral proteins is 
crucial in the generation of protective neutralizing antibodies.  MVA was used without 
complication during the smallpox eradication campaign, even in high risk populations (133), 
although its protective efficacy against human smallpox infection remains to be tested.  Recent 
vaccine trials have shown that MVA can be used without complication in HIV-infected 
individuals and also in those with atopic dermatitis (90).  Animal models using non-human 
primates indicate that MVA can protect against monkeypox infection (57, 58).   
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 A second strategy that has been used to increase the safety of vaccination is the 
identification and selective removal of genes that contribute to virulence.  The NYVAC vaccine 
is missing 18 open reading frames (ORFs), resulting in an attenuated virus.  NYVAC is avirulent 
in animal models (39, 72), but recent studies suggest that its immunogenicity is lacking 
compared to the traditional vaccines (139).  Single gene deletions have also been tested for their 
ability to produce an effective immune response and to protect against disease.  Deletion of the 
viral dsDNA binding protein, gene E3L, from wild-type VACV results in a 1000-fold decrease in 
pathogenicity in the mouse model (216), increased IFNγ-secretion from splenocytes of 
vaccinated mice (87), and protection against lethal challenge (87, 216).  An A41L gene (viral 
chemokine binding protein) deletion results in an increased T cell response and protection from 
lethal challenge, although this deletion was slightly more virulent than the wild-type virus (36).  
An MVA-based vaccine missing the soluble viral interleukin 1-beta (IL-1β) receptor (gene 
B15R) was avirulent in mice, induced a better T cell response, and provided better protection 
against challenge compared to wild-type virus (196).  Thus, identification and deletion of 
virulence genes appears to be a useful strategy in the production of safer poxvirus vaccines.             
Poxviruses as Platform Vaccines    
 Poxviruses are being used as platform vaccines for other infectious diseases and cancer, 
due to their ability to induce a robust immune response and to accommodate large pieces of 
foreign DNA.  Since wild type VACV has safety issues associated with it, poxvirus-based 
vaccine vectors are mostly made from the attenuated strains, such as MVA and NYVAC, or from 
host-restricted poxviruses, such as avipoxviruses, since these do not replicate in mammalian 
tissues.  Poxvirus-based recombinant vaccines have been made to express antigens from severe 
acute respiratory syndrome (SARS) (16, 35), influenza (24, 106), Leishmania major (203), HIV 
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(50), malaria (56), and rabies (154), among many others.  These vaccines produce long term 
memory and protection in animal models.  A promising new study reported that a canarypox-
based HIV vaccine was effective at preventing HIV infection in a community in Thailand (165).  
Thus, attenuated poxviruses are not only important as potential new generation vaccines for 
poxviruses, they are also attractive vectors for vaccines for other antigens.     
Poxviruses and the Immune Response 
Immune Responses to Poxvirus Infections  
Poxviruses are known for their ability to induce a robust immune response. Studies with 
humans and animal models have shown that a strong anti-virus antibody response follows 
infection with various poxviruses (57, 67, 218, 224), and that this response plays a role in 
protection.  In humans, antibodies are produced that can neutralize both IMV and EEV particles 
(48, 49) and virus-specific antibody is detectable for decades after immunization (43, 75, 156).  
Human Vaccinia Immune Globulin (VIG) is used in the treatment of many of the vaccine-related 
complications, highlighting the importance of antibody in viral neutralization and clearance.   
In mice, virus neutralizing IgM can be detected in the sera as soon as four days after 
infection (143).  Virus-specific isotypes of IgG can be detected by day 7 post infection (193) and 
remain elevated as far out as six weeks after infection in mice (221).  The production of virus-
specific IgG antibody is dependent on CD4+ T cells (224).  Mice that lack CD4+ T cells or 
major histocompatibility complex (MHC) class II fail to produce sufficient amounts of VACV-
specific IgG and are deficient in their ability to clear virus after primary infection with VACV 
(224).  The generation of antibody during an immunization has also been correlated with 
protection in mice after challenge with VACV (14).  In mice infected with ectromelia virus 
(mousepox), a humoral response was required to survive infection (32).  Mice lacking B cells 
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succumbed to infection later than those deficient in the CD8+ T cell effector response, 
suggesting a role for antibody in the later stages of a viral infection in this model.  The adoptive 
transfer of B cells or immune-serum from vaccinated mice to infected B cell deficient mice 
resulted in complete recovery (32).  Antibody, but not CD8+ T cell function, was shown to be 
necessary in the protection of primed mice from a challenge using virulent mousepox (151).  In 
this model, the antibody response was dependent on CD4+ T cell help.  This was shown by 
infecting mice that lacked either CD40 or MHC II, and were therefore unable to activate B cells 
through the CD40-CD40L interaction or lacked CD4+ T cells completely, respectively.  Similar 
to the mice deficient in B cell function, these mice succumbed to infection (151). 
In non-human primate models, IMV and EEV neutralizing antibody can be detected after 
about one week post infection (57), and antibody is necessary for protection from a lethal 
monkeypox challenge, as primates depleted of antibody-producing B cells prior to challenge did 
not survive (61). Together, there is an overwhelming amount of data to indicate that antibody is 
important both for the clearance of a primary infection and in mediating protection after 
vaccination. 
Poxviruses also induce a strong anti-virus T cell response, resulting in the clonal 
expansion of both CD4+ T cells and CD8+ T cells.  In humans, VACV-specific CD4+ and CD8+ 
T cells can be detected approximately one week after vaccination (131), and peak around two 
weeks (6).  The virus-specific CD8+ T cell response was greater than the CD4+ T cell response 
at these early times after vaccination (6) and both populations secreted mostly Th1 cytokines, 
including IFNγ (6).  Decades following vaccination, virus-specific T cells can be detected, but 
memory CD4+ T cells are longer lived than the memory CD8+ T cell population (6, 75).  In 
humans, cellular immunity appears to be crucial in the control of viral replication, as individuals 
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with deficiencies in cellular immunity can develop severe adverse reactions upon vaccination 
with VACV.   
In mice, anti-viral IFNγ-secreting CD4+ and CD8+ T cells can be detected approximately 
6-7 days following infection (76, 224) and both play an important role in the anti-viral defense 
against VACV or other poxviruses.  Mice depleted of CD4+ T cells were impaired in their ability 
to clear virus from target organs following infection with VACV, while those depleted of CD8+ 
T cells were similar to wild-type mice in their ability to control replication (224).  CD4+ T cells 
are important in the production of anti-viral CD8+ T cells (9, 92).  Mice depleted of CD8+ T 
cells do not survive primary infection with ectromelia virus (32), although they were not required 
for protection from a lethal secondary infection following vaccination (151).  CD8+ T cells can 
also provide protection against a VACV infection, as the adoptive transfer of memory CD8+ T 
cells to naïve mice resulted in decreased viral replication (224).  In another study, it was shown 
that mice that were vaccinated and then depleted of CD8+ T cells were not protected from 
sickness (191).  Thus, both CD4+ and CD8+ T cells play roles in immunity to poxviruses in 
mice.     
Poxvirus Immune Evasion Strategies 
While poxviruses can induce a robust immune response, they also encode numerous 
proteins that function to evade the host immune response.  These immunomodulators contribute 
to the virulence of poxviruses.  Many of these proteins were identified by their sequence 
similarity to known cellular proteins, indicating that they were likely captured from host 
genomes, while some evolved independently in the virus.  Described below are some of the 
proteins that poxviruses use to subvert the host immune response.     
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Vaccinia complement control protein.  The complement system involves an 
immunological cascade of proteins that function to opsonize pathogens.  Complement proteins 
can bind directly to the surface of a pathogen (alternative pathway) or can bind to either IgM or 
IgG that is bound to antigen (classical pathway).  The end result of either pathway is the 
formation and activation of the membrane attack complex and lysis of the cell.  VACV encodes a 
soluble 35 kilodalton (kD) polypeptide that has sequence similarity to host complement 
regulatory proteins (103).  This is now known as the Vaccinia virus complement control protein 
(VCP) and is encoded by VACV gene C21L (103).  Rabbits inoculated intradermally with a 
mutant virus lacking the C21L gene developed smaller lesions on the skin compared to rabbits 
inoculated with wild type VACV, indicating that the protein is an important virulence factor 
(83).  C21L was shown to inhibit the hemolysis of IgM-sensitized sheep red blood cells (RBC) in 
a hemolysis assay using serum as a source of complement (103).  When medium from wild type 
infected cells was added to the assay, lysis of the RBCs was prevented, but when medium from 
cells infected with a mutant virus lacking the 35 kD protein was added, the sheep RBCs were not 
protected from lysis (103).  VCP has subsequently been shown to bind to and inactivate two 
critical proteins of the complement cascade, C3b and C4b, and can inhibit both the classical and 
alternative pathways (15, 102, 134, 145).         
IL-18 binding protein.  IL-18 is an important inducer of IFNγ and the Th1 immune 
response, both critical components of the anti-viral defense.  This pro-inflammatory cytokine can 
be secreted by many cell types and is stored intracellularly as pro-IL-18 (69).  Before its release 
from the cell, pro-IL-18 is cleaved to its active form by the IL-1β-converting enzyme.  IL-18 
then works together with IL-12 to activate pathways that lead to the production of 
IFNγ, activation of natural killer (NK) cells, and induction of the Th1 response.  Many 
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poxviruses encode a soluble protein, encoded by the VACV gene C12L, with sequence similarity 
to cellular IL-18 binding proteins that can bind human and mouse IL-18 (18, 222), and can 
disrupt the activity of IL-18 in vitro (18, 190, 205, 222).  The protein also plays a role in 
virulence, as mice that were infected with a mutant virus lacking the IL-18 binding protein 
showed less weight loss and signs of illness compared to those that were infected with wild type 
virus (159, 205).  Further, the protein plays a direct role in modulating IL-18-driven immune 
responses.  Mice that were infected with the mutant virus had higher levels of virus specific NK 
(18, 159) and cytotoxic T lymphocyte (CTL) cytotoxicity (159) and had greater levels of IFNγ in 
samples collected from the lungs (159) than mice infected with wild type virus.     
Soluble tumor necrosis factor receptor homologs.  Tumor necrosis factor (TNF) is a 
potent pro-inflammatory cytokine that is secreted by numerous cell types.  TNF contributes to 
the antiviral immune response by binding its cellular receptor, and inducing apoptosis of virally 
infected cells and inhibiting viral replication.  TNF also works together with IFNγ to promote a 
Th1 immune response.  Thus, TNF is a key player in the host defense against viruses.  Many 
poxviruses, including myxoma virus, tanapox, VACV, VARV, ectromelia virus, and cowpox 
encode and secrete a TNF receptor homolog (vTNFR) (71, 121, 158, 176, 181, 226).  The 
vTNFR from each of these virus species can bind host TNF and block the biological activity of 
TNF in vitro (121, 158, 176, 181).  It has also been shown that deletion of the vTNFR in VACV 
results in decreased virulence in the mouse model (158)         
Soluble IL-1β  receptor homolog.  IL-1β is a pro-inflammatory cytokine secreted mostly 
by monocytes/macrophages.  It is also known as endogenous pyrogen since its major function is 
the induction of fever during an infection.  IL-1β is similar to IL-18 in that both are stored 
intracellularly as either pro-IL-1β or pro-IL-18 and then cleaved to their active forms by caspase-
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1 before being released from the cell (69).  Once released from the cell, IL-1β can bind its 
cellular receptor, leading to the production of pro-inflammatory cytokines, recruitment of 
lymphocytes to areas of infection and the induction of fever.  Not surprisingly, many poxviruses, 
including VACV (2), cowpox (192), and ectromelia virus (188) encode a secreted IL-1β decoy 
receptor (VACV gene B15R).  These virus encoded IL-1β receptors (vIL-1βR) can bind IL-1β 
(2, 192) and block its activity in vitro (192).  Interestingly, a vIL-1βR deletion mutant virus 
delivered intranasally to mice induced fever and was more virulent than wild-type virus (2).  
Vaccine strains known to naturally lack this decoy receptor have also been associated with 
greater virulence and induction of fever, and expression of the vIL-1βR in these strains reduced 
virulence and prevented fever (1).  These data led to the finding that IL-1β was the major fever-
inducing cytokine during a poxvirus infection (1).  An MVA virus lacking the vIL-1βR 
maintained its avirulent phenotype and induced greater T cell responses and better protection 
against lethal challenge compared to wild-type MVA (196).     
Chemokine regulators.  Chemokines are specialized cytokines that aid in the migration 
of immune cells to sites of infection.  These chemoattractants can be classified as either CC, 
CXC, or C chemokines, based on the order of conserved cysteine residues.  Different 
chemokines can be secreted by many cell types and bind specific receptors found on their target 
cells, thus orchestrating the influx of cells and the resulting immune response to the infection.  
Poxviruses have been shown to secrete a 35 kD protein (called CC chemokine inhibitor, vCCI) 
that preferentially binds CC chemokines (including RANTES, MCP-1, MIP-1α, and MIP-1β) in 
vitro (4, 25, 73, 187), thus blocking the binding of the chemokine to its cellular receptor.  vCCI 
does not have sequence similarity to any other known protein (4, 187).  This 35 kD protein can 
also inhibit the migration of cells in an in vitro monocyte chemotaxis assay (4, 187), and rabbits 
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infected with a mutant virus lacking the expression of the vCCI had significantly more 
lymphocytes in the pock lesions on the dermis (73).  Expression of vCCI in virus strains lacking 
the protein resulted in attenuation of disease and decreased numbers of lymphocytes in the lungs 
in the mouse model (160).  The protein has also been shown to be a promising therapeutic agent 
in diseases involving lung inflammation, such as asthma (44).  Poxviruses can also regulate 
chemokine activity by encoding chemokine homologs (46, 122).    
Interferon binding proteins.  Interferons (IFNs) are a group of potent antiviral 
cytokines.  IFNs bind their cellular receptor, activating the JAK/STAT pathway leading to the 
synthesis of many anti-viral proteins.  IFNs can be divided into two groups: type I IFNs (IFNα 
and IFNβ) and type II IFNs (IFNγ), each group having a distinct receptor.  IFNγ is secreted by T 
cells and NK cells, and induces the Th1 immune response, suppresses the Th2 response, 
activates macrophages, upregulates the expression of MHC molecules, and enhances CTL 
activity.  The production of Th1 cytokines is crucial to the clearance of poxvirus infections, 
while a Th2 response can increase virulence.  Indeed, mice that are given IFNγ during a poxvirus 
infection recover quicker than mice that do not receive treatment (93).  The importance of IFNγ 
in combating poxvirus infections is underscored by the numerous mechanisms that this group of 
viruses has evolved to counteract this response.  The VACV gene B8R encodes a soluble protein 
with sequence similarity to the extracellular domain of the human and murine IFNγ receptor 
(IFNγR).  The IFNγR homologs in VACV, cowpox, and camelpox have been shown to bind and 
inhibit the activity of IFNγ from human, cow, and rat, but not mouse (3, 142, 207).  The myxoma 
virus IFNγR can only bind IFNγ from rabbits, its natural host (212).  The protein is an important 
virulence factor, depending on the model used.  Disease is attenuated in rabbits, but not in mice, 
after infection with VACV lacking the IFNγR gene (142, 194, 207)
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virus homolog is an important virulence factor in mice and inhibits the generation of an optimal 
immune response in this model (174).  
 IFNα/β are also important anti-viral cytokines.  Type I IFNs can be secreted by immune 
cells and fibroblasts, and they upregulate the expression of MHC class I molecules, leading to 
enhanced recognition of virally infected cells by the host.  The VACV B18R gene encodes a 
secreted protein that can bind extracellular type I IFNs from numerous species and inhibit their 
anti-viral effects (37, 206, 214, 219), and also contributes to virulence in the mouse model (206).  
Interestingly, the soluble viral type I IFN binding protein can also bind to the surface of both 
uninfected and infected cells, where it blocks the action of the anti-viral cytokines, resulting in 
continued viral replication and spread (5).  The mousepox ortholog of VACV B18R binds mouse 
type I IFNs (189, 225) and is an important virulence factor (225).  Importantly, mice inoculated 
with a recombinant viral type I IFN binding protein were protected from a lethal challenge (225), 
suggesting that this protein may be used as a target for future vaccination.                            
Intracellular inhibition of interferon activity.  Since IFNs are such potent anti-viral 
cytokines, it is not surprising that poxviruses have evolved multiple strategies to thwart their 
effects.  In addition to the extracellular IFN binding proteins described above, poxviruses also 
encode proteins that inhibit the intracellular activity of IFN-responsive genes, most notably 
protein kinase R (PKR).  Once synthesized, PKR binds to dsRNA, a common product in the cell 
during a viral infection, and then, along with the eukaryotic translation initiation factor 2α 
(eIF2α), becomes phosphorylated.  eIF2α is then no longer able to initiate translation, and viral 
replication stops.  Another IFN-responsive gene that is expressed during a viral infection is 2’-5’ 
oligoadenylate synthetase that also binds dsRNA, ultimately resulting in the degradation of RNA 
and the inhibition of viral replication.  Poxviruses have two proteins that regulate IFN activity 
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intracellularly.  The E3L protein binds dsRNA, thus preventing it from binding to PKR and 2’-5’ 
oligoadenylate synthetase (31, 109, 128, 147).  The K3L gene product is similar to eIF2α and 
functions as a “pseudosubstrate” for PKR, preventing the phosphorylation of the cellular 
eIF2α (182).  The function of both proteins is to allow for the continued translation of viral 
proteins. 
Apoptosis inhibitors.  Apoptosis, or programmed cell death, is a highly regulated 
cellular process that can occur in response to viral infection.  The goal of the host is to eliminate 
the virally infected cells before progeny virions can be produced and infect other cells.  CD8+ 
cytotoxic T lymphocytes can recognize viral antigen presented in the context of MHC class I 
molecules and then selectively kill these cells by releasing cytolytic granules into the cell or by 
inducing apoptosis through the interaction of Fas with Fas Ligand.  Poxviruses encode genes that 
counteract both of these pathways.  Cowpox encodes a protein, CrmA, that inhibits the activity 
of caspase-8 (54), which is cellular protease involved in the transduction of apoptotic signals 
initiated by TNF or Fas receptors (209).  VACV encodes a gene similar to CrmA, designated 
B13R (53).  Both proteins can protect cells from Fas or TNF-induced cytolysis (53, 209).  A 
mutant VACV missing the B13R gene induced apoptosis in in vitro infected cells (99) and 
deletion of the cowpox ortholog resulted in attenuation of disease in the mouse model (120).  
Molluscum contagiosum also expresses a protein that interferes with apoptotic signaling via the 
Fas/TNF receptors (146, 184, 210).  Other poxviruses known to encode anti-apoptotic genes 
include ectromelia virus (21) and myxoma virus (64).  
Regulation of MHC class II antigen presentation.  MHC class II heterodimers present 
extracellular antigen to cognate CD4+ T cells.  Viral peptides, usually derived from the cytosol, 
can also be presented via MHC class II molecules by autophagy within the cell or when infected 
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cells are engulfed by professional antigen presenting cells (APC).  MHC class II has been shown 
to be important in poxvirus infections, as mice either depleted of CD4+ T cells or genetically 
void of MHC II molecules were deficient in their ability to clear a VACV infection, where those 
lacking CD8+ T cells cleared infection comparable to wild type mice (224).  In vitro MHC class 
II-restricted antigen presentation has been shown to be regulated by VACV using several 
different model systems.  Li et al (116) showed that VACV inhibited the presentation of 
numerous antigens (endogenous and exogenous) from several different professional APCs and 
fibroblasts.  MHC class II surface expression was unchanged as a result of infection and the 
underlying mechanism was shown to involve a decrease in the amount of peptide that was loaded 
into MHC class II molecules (116).  Another laboratory reported that in vitro VACV infection of 
primary Langerhans cells decreased their ability to become activated and present a model 
antigen, keyhole limpet hemocyanin (KLH), to a cognate CD4+ T cell line, HDK-1 (51).  
Primary rodent bone marrow derived macrophages infected in vitro with VACV were deficient 
in presenting lysozyme peptide to T cells (126).  It has also been shown that splenic dendritic 
cells from VACV-infected mice had reduced MHC class II surface expression and were impaired 
in their ability to present antigen to CD4+ T cells (227).  Thus, there is accumulating data to 
indicate that VACV can disrupt the processing and presentation of antigen via the MHC class II 
pathway, although none of the above mentioned manuscripts have identified the gene or genes 
responsible. 
Vaccinia Virus A35R Protein 
 While much work has been done to characterize poxvirus genes, more is needed.  In the 
subfamily Chordopoxvirinae, there are 90 genes that are completely conserved, and over 25 of 
these have yet to be characterized (213).  It has previously been shown that the VACV A35R 
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protein is highly conserved in all sequenced mammalian tropic poxviruses, but has little 
similarity to any other known protein, suggesting an important and novel function (170).  The 
hydrophobicity and location of the gene within the genome suggested that it was a membrane 
protein, but in a Triton X-114 partitioning assay, A35 partitioned to the aqueous phase, 
indicating that it is a cytoplasmic protein (170).  A35 is expressed early during infection, is non-
glycosylated, and is resolved at about 23 kD when probed with anti-A35 antibodies on a Western 
blot (170).  To determine the function of A35, a mutant virus was constructed in which A35 was 
replaced by a selectable marker, the E. coli xanthine guanine phosphoribosyl transferase (gpt) 
gene, and is designated as A35Δ (170).  A35Δ replicated similarly to the wild type Western 
Reserve (WR) strain of VACV, forming normal size plaques and normal quantities of 
intracellular and extracellular virus particles in BS-C-1 African green monkey kidney cells (170).  
Futhermore, A35 was not required for replication in numerous cell types from various hosts, 
indicating that A35 is likely not a host range gene (170).  To determine the role of A35 in 
virulence, mice were intranasally (i.n.) infected with 104 plaque forming units (pfu) of either 
WR, A35Δ, or an A35 rescue virus (A35Res) (or mock-infected with phosphate buffered saline, 
PBS, as a control), and their weights were measured daily as an indicator of sickness (170).  
Mice that were infected with either of the viruses containing A35 (WR and A35Res) rapidly 
began to lose weight at about 6 days post infection (dpi) (2 out of 6 WR died), while those 
infected with the A35Δ virus grew similar to PBS control.  Mice were also infected with 105 and 
106 pfu, and it was determined that the A35 protein increases virulence by 100- to 1000-fold.   
 Previous data with A35 indicated that the protein was not involved in replication in eight 
different cell lines from various hosts, but that it was required for full virulence in the mouse 
model.  We therefore hypothesized that the protein may promote virulence by affecting viral 
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replication in certain cell types or tissues in vivo or by regulating the host immune response.  To 
test for the role of A35 in replication, we have compared the replication of WR to A35Δ using 
various cell lines, primary cells, and in vivo infected mouse tissues.  To test for the role of A35 in 
regulation of the immune response, we have used two approaches.  The first involves an in vitro 
MHC class II restricted antigen presentation system using primary rat macrophages as APC.  We 
found this to be an appropriate system to look at since rats are natural reservoirs for poxviruses 
and peritoneal exudate cells (PEC) are a rich source of macrophages.  For most of the in vitro 
assays, both mouse and rat cells were used.  We were also interested in looking at MHC class II 
antigen presentation because during a VACV infection, mice deficient in MHC class II or CD4+ 
T cells are suppressed in their ability to control viral replication (224) and have lower amounts of 
virus-specific antibody and CTL.  This is in contrast to mice deficient in MHC class I or CD8+ T 
cells that are able to clear an infection similar to wild type mice (224).  The second approach to 
determining the role of A35 on the host immune response involves infection of mice with either 
A35Δ or WR, and then performing ex vivo assays to determine virus-specific antibody 
production, CTL killing, and IFNγ production.  We also constructed an A35 mutant virus in the 
attenuated vaccine strain MVA (MVA35Δ) and similar experiments were performed comparing 
the replication and immunogenicity of MVA to the MVA35Δ virus.  We have also tested the 
protective efficacy of the A35Δ and the MVA35Δ viruses compared to wild type WR or MVA, 
respectively.  The data presented provide strong evidence that A35 is an important poxvirus 
immunoregulator, and that A35 deletion mutant viruses can provide protection against a lethal 
respiratory challenge similar to wild type viruses.   
.    
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Abstract 
 Vaccinia virus (VACV) is the current live virus vaccine used to protect humans against 
smallpox and monkeypox, but its use is contraindicated in several populations because of its 
virulence.  It is therefore important to elucidate the immune evasion mechanisms of VACV.  We 
found that VACV infection of antigen-presenting cells (APCs) significantly decreased major 
histocompatibility complex (MHC) II antigen presentation and decreased synthesis of 13 
chemokines and cytokines, suggesting a potent viral mechanism for immune evasion.  In these 
model systems, responding T cells were not directly affected by virus, indicating that VACV 
directly affects the APC.  VACV significantly decreased nitric oxide production by peritoneal 
exudate cells and the RAW macrophage cell line in response to lipopolysaccharide (LPS) and 
interferon (IFN)-γ, decreased class II MHC expression on APCs, and induced apoptosis in 
macrophages and dendritic cells.  However, VACV decreased antigen presentation by 1153 B 
cells without apparent apoptosis induction, indicating that VACV differentially affects B 
lymphocytes and other APCs.  We show that the key mechanism of VACV inhibition of antigen 
presentation may be its reduction of antigenic peptide loaded into the cleft of MHC II molecules.  
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These data indicate that VACV evades the host immune response by impairing critical functions 
of the APC. 
Introduction 
Poxviruses are large, double stranded DNA viruses (~200 kb) that replicate in the 
cytoplasm of host cells (141).  Poxviruses have worldwide distribution and are highly successful 
pathogens, infecting a tremendous variety of animals including insects, reptiles, birds and 
mammals. The most infamous member of Family Poxviridae is smallpox, which is estimated to 
have caused 500 million human deaths in the 1900’s before its eradication from nature (124).  
The eradication of smallpox was due to the most successful vaccination campaign in history 
using a related virus, Vaccinia virus (VACV).  Today there remain multiple poxvirus threats to 
humans, including the use of smallpox as a bio-terrorism weapon in a now largely unvaccinated 
population.  New poxviruses are identified each year in animal populations, and several zoonotic 
poxviruses appear to be emerging worldwide: Cantagalo in South America (45), Tanapox in 
Africa, Europe and the USA (52, 198), and buffalopox in India (100).  Molluscum contagiosum 
virus causes wart-like lesions, occurs commonly in humans (101), is now emerging as a sexually 
transmitted disease, and accounts for approximately 300,000 doctor visits each year in the U.S. 
(140).  The most dangerous poxvirus extant today is monkeypox virus, which causes a smallpox-
like illness in humans, is endemic to Africa, and caused an outbreak in humans in the USA in 
2003 (34).  Studying the immune evasion tactics of this virus family will shed light on how these 
viruses evolved into such successful pathogens. 
While VACV is used as a live virus vaccine, it can also be pathogenic.  In a report on 
almost 39,000 volunteers vaccinated as first responders, it was found that 1 of every 450 
vaccinees had to be hospitalized due to adverse vaccine reactions and that 1 death occurred per 
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13,000 vaccinations (29). Vaccination is contraindicated for individuals with any history of 
eczema or immunodeficiency disorders because fatalities may occur.  Otherwise-healthy 
individuals can acquire a disseminated poxvirus rash, myopericarditis, and rarely fatal 
encephalitis from vaccination (7, 29, 60, 211).  Understanding viral evasion mechanisms will aid 
in the development of safer vaccines.   
For healthy individuals, an effective immune response limits viral replication of the less 
pathogenic poxviruses. However, poxviruses encode a plethora of immuno-modulatory proteins, 
including proteins that block apoptosis, chemokine and cytokine binding and synthesis, and cell 
signaling (74, 141, 181).  In addition, poxviruses directly infect human and rodent immune cells 
both in vivo and in vitro, including lymphocytes, natural killer (NK) cells, and 
monocytes/macrophages (149, 175) and have been shown to decrease antigen presentation in 
several types of APC (116, 227).  We wanted to further explore the effects of VACV on antigen 
presentation interactions between APC and the responding T cells and were especially interested 
to study primary APC responding to an inflammatory stimulus, as this has not been previously 
studied.  We chose to use rat peritoneal macrophages elicited by injection of killed 
Corynebacterium parvum to study how virus interacts with primary APC that would be recruited 
to a site of infection/inflammation (38, 108).  Also, we were interested to explore how VACV 
interacts with the rat immune system, as rats are a natural reservoir for orthopoxviruses and can 
transmit them to primates (34, 129).  While the natural host of VACV is unknown, several 
orthopoxviruses spread naturally in rodents, including rats (34, 129).  Here we describe the 
effects of VACV on a MHC class II restricted antigen presentation system in which rat 
macrophages present a peptide of myelin basic protein to cognate antigen specific CD4+ T 
lymphocytes (127, 155).  CD4+ T cells are crucial for viral clearance in poxvirus infection (92, 
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151).  In addition, we explore viral effects on T and B lymphocytes, dendritic cells and 
macrophage lines.  Our data indicate that VACV-infection rapidly disables various APC by 
affecting relevant cell surface proteins, and in some cases inducing apoptosis of APC, thus 
blocking downstream T cell activation events and cytokine production. Further, our data indicate 
that the mechanism of immune interference is not necessarily apoptosis-dependent as has been 
previously suggested (95), but rather VACV blocks presentation of antigenic peptides in MHC 
class II molecules.   
Materials and Methods 
Cells and Virus 
VACV Western Reserve (WR) stocks were propagated using BS-C-1 cells as previously 
described (170).  For titrations of VACV, BS-C-1 monolayers were fixed and stained with 0.1% 
crystal violet in 20% ethanol.  All cells were grown in media containing 10% fetal bovine serum 
(FBS).  CD4+ RsL-11 T cell clones were derived and maintained as previously described (127).  
CTLL-2 (ATCC # TIB-214) were maintained in RPMI supplemented with 0.4% IL-2 (127).  
RAW 264.7 (ATCC # TIB-71), a mouse macrophage cell line, was maintained in DMEM. The 
mouse B cell line 1153 and the T cell hybridoma B04 (HEL74-88 specific) (kind gifts from Janice 
Blum) were maintained in RPMI (116). 
Peritoneal Macrophage Isolation and Antigen Presentation Assays 
Lewis rats (bred and maintained at the AAALAC-certified Brody School of Medicine 
animal care facility at East Carolina University) were injected intraperitoneally (i.p.) with 200 µg 
of inactivated C. parvum in 5 ml of HBSS.  Two to three days later, the rats were sacrificed and 
peritoneal exudate cells (PEC) were harvested by washing the peritoneum in cold HBSS.  PEC 
were washed, infected for 5 h, and placed into 96-well plates.  PEC were incubated in 
 24  
quadruplicate with 50-500 nM guinea pig myelin basic protein (GPMBP) for 30 minutes, 
followed by addition of 25,000 Lewis rat CD4+ RsL.11 clones specific for GPMBP.  For 
experiments involving 1153 B cells, 25,000 B cells (I-Ab) were infected for 6 h.  Cells were then 
plated in a 96-well format and incubated with varying concentrations of the antigen HEL74-88 
(gift from Janice Blum) for 1 h.  25,000 B04 T cells specific for the HEL74-88 peptide in the 
context of I-Ab were added to each well.  The antigen presentation plates were incubated for 24-
48 h at 37ºC, 5.0% CO2. After incubation, 50 µl of supernatants were transferred into an empty 
96-well plate and frozen for the following assays.  All animal experiments were in compliance 
with East Carolina University Animal Care and Use committee (K139) and NIH guidelines. 
Bone Marrow-Derived Dendritic Cells 
Rat bone marrow was harvested from femur and tibia.  The cells were placed in RPMI 
supplemented with 10% FBS, 1% L-glutamine, 1% penicillin-streptomycin, and 0.1% 
granulocyte macrophage-colony stimulating factor- (GM-CSF-) containing baculovirus 
supernatant.  After 3 days of culture, the culture medium was removed and replaced with fresh 
culture medium.  On day 7, the dendritic cells were collected and used for the antigen 
presentation assay and flow cytometry analysis.  
CTLL IL-2 Bioassay 
IL-2 was measured using previously described methods (127).  Briefly, 10,000 CTLL 
clones (quadruplicate) were washed, resuspended in RPMI, and added to the collected 
supernatants.  The plates were incubated for 48 h at 37ºC, 5.0% CO2, followed by the addition of 
10 µl of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)2H-
tetrazolium, inner salt/phenazine methosulphate (MTS/PMS) (2.0 mg/mL MTS, Promega; and 
0.1 mg/mL PMS, Sigma) (40).  The absorbance was read at 24, 48, and 72 h post MTS/PMS at 
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492 nm filtered, and 690 nm reference.  Media only was used to define the background control 
level and known IL-2 containing supernatants were used as positive control. 
Nitric Oxide (NO) Measurement 
Griess Reagent (50 µl) (1% sulfanilamide–0.1% N-[1-naphthy] ethylenediamine in 2.5% 
phosphoric acid) was added to 50 µl of the quadruplicate harvested supernatants.  The 
absorbance was read at 540 nm after a 5-minute incubation at room temperature (27). 
Measurement of Cytokines 
50 µl of the harvested supernatants (triplicate) were analyzed using the LincoPlex 24 Rat 
Cytokine/Chemokine Luminex Bead Immunoassay Kit according to the manufacturer’s 
instructions (Linco Research).  The supernatants were incubated with a panel of anti-cytokine 
antibodies immobilized on Luminex beads (Bio-Rad Laboratories).  The following cytokines 
were analyzed: IL-1α, IL-1β, IL-2, IL-6, IL-17, IL-18, MIP-1α, GM-CSF, IFN-α, growth 
regulated oncogene alpha/keratinocyte attractant (GRO/KC), RANTES, TNF-α, MCP-1, eotaxin, 
G-CSF, IL-4, IL-9, IL-13, IL-5, and IL-10.  Samples were run according to the manufacturer’s 
instructions (Bio-Rad) and analyzed on the BioPlex protein array reader (Bio-Rad) in the Duke 
University Human Vaccine Institute Immune Reconstitution Core Facility (Durham, NC).           
RsL.11 Stimulation Assay 
CD4+ RsL.11 T lymphocytes were washed and resuspended in RPMI.  The cells were 
infected for 3-4 h, plated in tripliciate in a 96-well format, and stimulated with PEC/50 nM 
GPMBP, 25 µg/ml Con A (Sigma), or 100 nM phorbol 12-myristate 13-acetate (PMA)/2 µM 
ionomycin (Sigma).  The plates were incubated at 37o, 5% CO2.  50 µl of the harvested 
supernatants were collected at 20- and 40-h and assayed for IL-2 using the CTLL bioassay 
already described. 
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Metabolism Assays 
PEC or RAW 264.7 macrophages were infected with VACV multiplicity of infection=2 
(MOI=2) and 1153 B cells at an MOI of 5. Metabolism was measured by the addition of 10 µl 
MTS/PMS 4-24 hpi, and analyzed similarly to the method described above for the CTLL IL-2 
Bioassay.  Absorbance was read at 492 nm at various times post infection. 
Flow Cytometry 
Cells were infected for 4 hours and then washed in FACS buffer (PBS containing 0.1% 
heat-inactivated FBS and 0.1% sodium azide).  3 x 105 cells were stained with an anti-MHC II 
concentrated supernatant (Y3P, AF6120, and MKS4) or OX1 anti CD45 for 1 h on ice, washed 
once, and then incubated with a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
IgG (Southern Biotech). MHC II expression was measured using a FACScan (Becton Dickinson) 
equipped with the Cell Quest software.   For apoptosis measurement, cells were infected and 
then stained with annexinV-FITC/propidium iodide (PI) (BD Pharmingen) per the 
manufacturer’s instructions.  
One-Step Growth Curve 
A one-step growth curve was obtained to measure viral replication in permissive cells 
and PEC as previously described (170).  
Peptide-MHC Association 
The Y-Ae antibody specifically detects a complex of peptide 52-68 from I-Ed MHC class 
II bound in the cleft of MHC class II I-Ab (84, 173).  This complex is formed in mice that 
express both alleles.  Spleens were harvested from B10.A-H2^i5 H2-T18^a/(5R)SgSnJ mice 
(Jackson Labs); C57BL/6 mice were used as a negative control.  Unfractionated splenocytes 
were infected with purified virus for 3 h (MOI=10) and then incubated with biotin-conjugated Y-
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Ae (eBioscience).  Cells were washed and incubated with streptavidin-R phycoerythrin (RPE) 
(Southern Biotech).  Samples were analyzed using a FACScan equipped with Cell Quest 
software. 
Statistical Analysis 
Experiments were repeated 3 times and representative data with standard deviation bars 
are shown.  A two-tailed Student’s t test was used to compare uninfected with VACV-infected 
groups.  p values < 0.05 were considered significant.    
Results 
VACV Decreases IL-2 Production 
As antigen presentation is the seminal event triggering an adaptive immune response, we 
wanted to assess the effects of VACV infection on this pivotal point of the immune response 
using primary cells recruited to a site of inflammation.  Peritoneal exudate cells (PEC) were 
harvested from rats, infected with VACV, and pulsed with a model antigen (GPMBP).  Various 
numbers of infected cells were then incubated with cognate CD4+ T cells.  In order to measure 
antigen presentation responses, supernatant IL-2 was measured.  VACV infection significantly 
(Student’s t test p<0.05) reduced IL-2 production by T cells 15-48 hpi (Fig 1a).  VACV also 
significantly decreased IL-2 production using rat splenocytes (Fig 1b), dendritic cells (Fig 1c), 
and PEC that had been rested overnight prior to infection (not shown) as APC. In the absence of 
antigen or either cell type, no IL-2 was produced.  Together, these data indicated that VACV 
significantly decreased the amount of IL-2 that is produced by CD4+ T lymphocytes. 
VACV Decreases NO Response 
During antigen presentation, both the T lymphocyte and the APC become activated, and 
macrophages are stimulated to produce nitric oxide (NO) (123), an important antiviral defense.  
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Using the same antigen presentation system described above, supernatants were assayed for the 
production of NO.  Uninfected PEC produced increasing amounts of NO with increasing 
numbers of APC (Fig 1d), while VACV-infected PEC were markedly impaired in their ability to 
secrete NO.  NO was not produced in the absence of antigen or either cell type (data not shown), 
indicating that this is a specific antigen presentation response.  These results indicated that both 
T lymphocyte and macrophage responses were suppressed by VACV. 
RsL.11 T Cells are Refractory to VACV 
We next sought to determine which cell type was being directly affected by VACV in 
this antigen presentation system.  While we intentionally incubated VACV with APCs 
(macrophage, splenocytes and dendritic cells) prior to addition of T cells, the RsL.11 T cells 
could have become infected during co-incubation with the infected APC.  To assess the effects of 
virus infection on IL-2 production by the RsL.11, RsL.11 T cells were incubated in triplicate 
with VACV for 3 h, washed, and then incubated with a titration of uninfected PECs pulsed with 
antigen, similar to the above-described experiments.  As shown in Fig 2a, VACV did not 
significantly decrease IL-2 production when pre-incubated with T cells.  We also assessed the 
effect of VACV infection on RsL.11 responses to mitogenic and chemical stimulation.  RsL.11 T 
cells were incubated with VACV for 4 h, and then stimulated for 24 to 48 h with Con A, PMA 
and ionomycin, or uninfected antigen (Ag)-pulsed PECs.  VACV did not significantly decrease 
IL-2 production by RsL.11 T cells in response to any of these stimuli (Fig 2b).  Control groups 
included the stimulants in media with no RsL.11 T cells and did not give readings above 
background in the IL-2 bioassay.  These data suggest that RsL.11 IL-2 synthesis and secretion is 
not affected by VACV.  
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To determine whether RsL.11 T cells could be affected by VACV, we also measured 
cellular proliferation after incubation with virus.  RsL.11 T cells were incubated with VACV for 
10 h, and then MTS/PMS was added to measure metabolism.  VACV did not significantly affect 
the RsL.11 T cell metabolism up to 64 h post infection (hpi) (Fig 2c). These data suggest that 
RsL.11 T cells are completely refractory to VACV.  We therefore incubated RsL.11 T cells with 
infectious virus and compared progeny virus production to a known permissive cell line, BS-C-1.  
After 72 h, a 100-fold increase in virus was measurable in infected BS-C-1 cells, but no increase 
in virus could be detected in cells or supernatants of RsL.11 T cells, indicating that they are non-
permissive for VACV infection (data not shown).  Thus, there is no evidence that these cells 
even become infected under these conditions. 
CTLLs and VACV Infection 
As CTLL cells were used to measure IL-2 in supernatants, it was also possible that 
VACV might be affecting the ability of the CTLL to proliferate in response to IL-2.  To assess 
virus effects on CTLL, we incubated the CTLL with VACV for 5 h and then measured 
proliferation in response to IL-2-containing supernatants (155).  The addition of IL-2 to the 
media increased the metabolism/proliferation of the uninfected CTLLs over the proliferation of 
CTLLs incubated with no IL-2 (Fig 2d), and VACV did not significantly reduce this response.  
As the amount of virus used in this experiment was four times higher than levels contained in 
supernatants from antigen presentation assays, it is unlikely that VACV affected CTLL 
responses to IL-2 in the antigen presentation assay.  Together these data suggest that VACV acts 
directly on the APCs, not the T cells used in these assays. 
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Antigen Concentration 
As the T lymphocytes in these assays were minimally affected by VACV infection, we 
theorized that the APCs were being affected by VACV and that increasing antigen 
concentrations might overcome the VACV-induced decrease in antigen presentation capacity.  In 
infected PECs presenting antigen to RsL.11 T cells (similar to experiments depicted in Fig 1), a 
titration of GPMBP antigen (50-250 nM) showed that higher antigen concentrations augmented 
the weak antigen-presenting capacity of infected APCs (Fig 3).  In contrast, increasing antigen in 
this concentration range did not significantly enhance the efficiency of uninfected APCs to 
stimulate IL-2 production.   
B Cell Antigen Presentation 
We next determined if VACV affects antigen presentation by a murine B cell line.  The 
mouse 1153 B cell line presents the HEL74-88 peptide to the CD4+ B04 T cell line (116).  1153 B 
cells were infected for 6 h, incubated with varying concentrations of the HEL74-88 peptide, and 
then incubated with the cognate B04 T cell line.  The presence of VACV significantly 
suppressed B cell antigen presentation (IL-2 production, Fig 4a) (Student’s t test p<0.01).  To 
assess viral effects on the B04 T cells, T cells were incubated with virus for 24 h, at which time 
MTS/PMS was added in order to measure metabolism.  VACV did not affect the 
proliferation/metabolism of the B04 T cells up to 70 hpi (Fig 4b), suggesting that the T cells 
were also not directly affected by VACV in this antigen presentation system.  These data indicate 
that VACV blocks antigen presentation of multiple antigens presented by various APCs from 
both rats and mice. 
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VACV Inhibits NO Production from PEC and RAW Macrophages 
In order to study VACV regulation of isolated APCs, we used LPS and IFNγ to stimulate 
PECs and the RAW 264.7 murine macrophage cell line (157).  PECs and RAW cells were 
infected for 4 h, stimulated with LPS, IFNγ, or both, and supernatants were assayed for NO.  All 
stimuli induced NO production in uninfected PECs and RAW cells; however, this induction was 
significantly (Student’s t test p<0.05), and in some cases completely, blocked by VACV-
infection (Fig 5). These data suggest that macrophages are highly sensitive to VACV infection.  
VACV Infection Globally Alters Cytokine Responses in Antigen Presentation 
As the result of antigen presentation, both the APC and the responding T cell produce 
numerous cytokines initiating the specific immune response.  As VACV inhibited the amount of 
both IL-2 and NO produced in this rat model of antigen presentation, we assessed the effect of 
VACV on synthesis of other cytokines and chemokines.  Using a multiplex bead-based assay, we 
determined that VACV reproducibly and significantly (p<0.05) inhibited the production of MIP-
1α, IL-1β, IL-1α, IL-2, IFNα, GRO/KC, RANTES, TNFα, and MCP-1 (Fig. 6) in response to 
PEC antigen presentation to RsL.11 T cells.  These data confirm the IL-2 bioassay results in Fig 
1.  In addition, VACV decreased the secretion of IL-6 and GM-CSF; however the reduction was 
not always significant.  Interestingly, VACV infection did not inhibit IL-18 production.  
VACV Decreases MHC Class II Expression 
Because VACV infection decreased MHC class II-mediated antigen presentation, we 
assessed the effects of VACV on the expression of MHC II molecules on the surface of PECs.  
PECs were infected for 4 h, and MHC II expression was measured by flow cytometry. In three 
experiments, VACV mildly decreased MHC class II surface expression.  For example, compared 
to uninfected PECs, VACV decreased the percentage of high-expressing MHC II-positive cells 
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from 47% to 37% (Fig 7; mean fluorescence intensity, MFI, 26 +/- 0.3 versus 19.7 +/- 1.8).  We 
also assessed the ability of VACV to inhibit MHC II expression in 1153 B cells.  1153 B cells 
were infected and MHC II expression was measured as above. In uninfected 1153 B cells, 38% 
expressed high levels of MHC II, while only 15% of VACV-infected B cells were class II bright 
(Fig 7; MFI 144 +/- 13.4 versus 76 +/- 2.8).  These data indicated that VACV decreases MHC II 
expression on APCs soon after infection. In the same experiments, VACV infection did not 
decrease CD45RO expression, indicating that the reduction observed was specific and not just a 
consequence of general membrane protein perturbation caused by viral infection.      
VACV Induces Apoptosis in PEC and RAW Macrophages 
Because VACV infection blocked PEC responses, we assessed the effects of VACV on 
the viability of the PECs.  PECs were infected with VACV in triplicate, and metabolism was 
measured through the reduction of MTS/PMS.  Differences in metabolism between the groups 
became apparent 24 hours post infection (hpi) (Fig 8a), suggesting that the virus is killing cells.  
However, VACV had only a minor effect on 1153 B cells (Fig 8b), even at 100 hpi.  We 
therefore measured the ability of VACV to induce apoptosis in these cells using PI and annexin 
V.  It was previously reported that VACV induces apoptosis of the murine macrophage J774 cell 
line (80).  VACV infection increased early apoptotic cell percentages in PECs from 16% to 42% 
and in the RAW 264.7 macrophage line from 14% to 53% (Fig 9) at 4 hpi.  VACV induced 
apoptosis similarly in rat bone marrow-derived dendritic cells and mouse splenic dendritic cells 
(data not shown). However, using similar assays we could not detect VACV induction of 
apoptosis in three experiments in the 1153 B cell line (Fig 9) from 6 to 24 hpi, even though 
VACV also suppressed antigen presentation by this line.  
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Viral Replication 
Induction of apoptosis in virally infected cells is one host defense against virus 
replication, and VACV has been reported to induce apoptosis in macrophages and dendritic cells 
(22, 80).  We therefore determined the ability of VACV to replicate in PECs compared to BS-C-
1 cells, which are permissive for viral replication.  Figure 10 shows that VACV-WR was able to 
increase infectious virus particles 2-logs by 30 hpi in BS-C-1 cells, but no replication was 
apparent in PECs at 10, 20, or 30 hpi.  Thus VACV may induce apoptosis in professional APCs 
and block their function, but the virus also sacrifices the ability to replicate in the cells.   
Peptide Association with MHC Class II 
One level of immune regulation, both in homeostasis and infection, lies in controlling the 
association of peptides with the MHC molecules that present them (82).  As VACV inhibits 
antigen presentation, but only modestly affects class II MHC expression, we tested the effect of 
VACV on peptide loading in the MHC class II employing the Y-Ae antibody.  The Y-Ae 
antibody specifically detects a complex of peptide 52-68 from I-Ed MHC class II bound in the 
cleft of MHC class II I-Ab (84, 173).  MHC class II molecules frequently present self peptides 
from surface proteins that recirculate through endosomes and are degraded, similarly to 
exogenous antigens that are internalized.  The Y-Ae antibody recognizes a major determinant 
(approximately 12% of MHC molecules) in mice expressing both of these class II molecules 
(173, 200).  We measured the amount of peptide bound in the cleft of MHC class II molecules on 
the surface of uninfected and VACV-infected spleen cells.  As Fig 11 shows, 63% of uninfected 
cells expressed MHC class II molecules complexed with this I-E peptide, while only 30% of 
VACV-infected cells were positive 3 hpi (MFI 78.2 +/- 9.6 for uninfected cells compared with 
38 +/- 2.8 for VACV-infected cells).  In contrast, surface MHC class II I-Ab levels were only 
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modestly reduced (Fig 11). These data indicate that VACV interferes intracellularly with the 
expression of surface proteins required for antigen presentation and specifically blocks 
expression of peptide-loaded MHC class II.  
Discussion 
We have shown here that VACV blocks class II MHC antigen presentation by primary 
rodent cells, including unfractionated splenocytes, PECs, dendritic cells, and by a B cell line. 
This likely represents an evolved immune evasion mechanism that is advantageous to the virus 
even though the virus sacrifices the ability to replicate progeny virions in APCs.  Responses to 
antigen presentation of both CD4+ T lymphocytes and the APCs are inhibited (Fig 1) and this 
has the overall effect of limiting downstream cytokine and chemokine production (Fig 6) and 
presumably multiple aspects of the anti viral immune response.  Notably, many of the cytokines 
that are regulated by VACV are chemotactic factors (MIP-1α, IL-1, TNF-α, GRO/KC, 
RANTES, and MCP-1), which aid in the migration of immune response cells to sites of 
inflammation and infection. 
We have found the T lymphocytes used here to be refractory to virus effects, with VACV 
directly affecting the APCs.  It has been reported in humans that VACV preferentially infects 
subsets of CD14+ cells, B cells to a lesser extent, and only activated primary T cells (30).  Our 
results are similar to work recently published showing that VACV decreases MHC class II 
antigen presentation in B cell, fibroblast, and macrophage cell lines, as well as primary immature 
dendritic cells (116).  Antigen presenting capacity could be partly restored in our studies by 
increasing the amount of antigen, suggesting that some process of antigen uptake or processing 
or presentation is blocked.  Data from the Blum laboratory indicate that intracellular antigen is 
not the limiting factor (116).  We found that VACV alters class II MHC expression in APCs 
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within a few hours after infection.  This may simply be a consequence of apoptosis induction as 
we and others have shown that VACV induces apoptosis in human and rodent macrophages and 
dendritic cells (22, 80). Other groups have shown a decrease in CD86 and MHC class II on 
human dendritic cells correlating with apoptosis induction and reduced ability to present antigen 
(62, 95).  VACV modulation of class II MHC has been controversial.  Other groups have shown 
VACV-induced increases in MHC class II, but with inhibition of maturation-induced MHC class 
II, class I, CD86, and CD80 (86).  Some differences may be attributable to the type of 
preparation of virus used to infect APCs, since the ‘crude’ virus preparation normally used for 
infections is a cell lysate, which can act as an inflammatory stimulus. Another group recently 
reported that VACV decreased MHC II-restricted antigen presentation by specifically inhibiting 
the expression of surface MHC class II on splenic dendritic cells isolated from VACV-infected 
mice (227).  We did not measure the amount or stability of MHC class II proteins in our studies 
because other laboratories have shown that the amount of MHC protein is not directly related to 
its functional surface expression.  For example, peptide-MHC complexes can be inhibited with 
no decrease in the amount of MHC class II proteins in cells (116), and MHC class II mRNA 
levels can be decreased with no decrease in MHC class II surface expression (227).  In summary, 
there is growing evidence to indicate that VACV modulates MHC class II-restricted antigen 
presentation by specifically affecting functions of the APC.     
Interestingly, the inhibition of antigen presentation appears distinct for professional APCs 
and the 1153 B cell line.  Class II MHC expression was reduced in this B cell line, but, unlike 
other APCs, apoptosis was not detected.  This suggests that VACV may decrease class II even in 
the absence of apoptosis induction.  Importantly, we have shown that VACV strongly reduced 
the amount of peptide in the cleft of MHC class II on infected primary APCs by flow cytometry.  
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These data are supported by a study in a human B cell line where VACV infection decreased 
peptide association with MHC class II measured by western blot (116).  As this effect is 
demonstrable with different antigens in different cells, it is likely that this is a key mechanism 
used by VACV to suppress immune responses.   How this occurs is currently under 
investigation.  
We do not believe that VACV simply reduces antigen presentation because it kills 
infected cells.  First, we show in Fig 3 that increasing antigen concentrations restore antigen-
presenting capacity in VACV-infected cells, suggesting that the cells are not dead, but rather 
disabled in terms of antigen presentation.  In Fig 8, we show that differences in the metabolism 
of APCs are not seen until almost 24 hpi, but that VACV reduces the surface expression of MHC 
class II and the amount of peptide in its cleft by 5 hpi, and the antigen presentation-induced T-
cell responses have been diminished by 15 hpi of APC.  In addition, VACV does not induce 
apoptosis in 1153 B cells, but still blocks their antigen-presenting capacity and MHC class II 
expression (Figs 4 and 7).  Together, these data suggest a specific VACV-induced inhibition of 
antigen presentation.   
We studied antigen presentation in rodent cells.  As most extant poxviruses have evolved 
a broad host range, the immunomodulatory mechanisms appear to be conserved and functional in 
a number of host species.  For example, rats are a natural host for cowpox virus and can transmit 
it to primates, as demonstrated by a recent outbreak in a primate colony in Europe with 
widespread fatalities (129, 132).  Most VACV APC work has been undertaken in the mouse 
model; our results show that VACV blocks antigen presentation and T cell priming in a rodent 
known to transmit orthopoxviruses to primates. 
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VACV caused an apparent broad decrease in post-antigen presentation cytokine 
production. The notable exception to VACV inhibition was Il-18.  IL-18 is stored intracellularly 
as pro-IL-18 and rapidly released upon stimulation (69).  As IL-18 is an important factor in the 
induction of anti-viral IFNγ production, its storage for rapid release may be an evolved host 
mechanism to contravene immunomodulation by viral gene products.  The importance of this 
cytokine in antiviral defense is underscored by the possession of an IL-18 binding protein 
encoded by poxviruses (159).  VACV produces several soluble cytokine binding proteins that 
may interfere with detection of these cytokines if, and only if, they block binding of the detection 
antibody.  However, because there is a general decrease in cytokine production it seems unlikely 
that the decrease would be caused by VACV-specific binding proteins. 
VACV rapidly decreases antigen presenting capacity, alters expression of class II MHC 
and induces apoptosis in multiple APC types, including peritoneal macrophages responding to 
inflammatory stimuli.  These data expand our knowledge of viral interference mechanisms and 
suppression of immunity that contribute to poxvirus pathogenesis, however, the viral gene 
products involved in this inhibition and the intracellular mechanisms remain to be elucidated.  
An increased understanding of poxviral pathogenesis will aid in the development of antiviral 
drugs and novel tailored vaccine strains, which exclude immunosuppressive poxviral genes, but 
which retain and efficiently express the protective antigenic target epitopes that stimulate the 
immune system.     
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Figures 
Figure 1: VACV infection of primary APC inhibits IL-2 and NO production.  Freshly 
isolated PEC (a), splenocytes (b), or dendritic cells (c) were isolated from a rat, infected with 
VACV WR (MOI=2) for 5 h, pulsed for 30 minutes with 50 nM GPMBP, and then incubated 
with the cognate CD4+ RsL.11 T cell line.  Uninfected PECs served as a control.  At 15 to 48 
hpi, supernatants (50 µl) were collected and assayed for either IL-2 using the IL-2 dependent cell 
line CTLL (a-c) or for NO using Greiss reagent (d). For the CTLL bioassay, media only was 
used to define the background control level and known IL-2 containing supernatants were used 
as a positive control.  Proliferation was read as absorbance at 492 nm.  IL-2 production was 
determined as the mean optical density (OD) value of the experimental group minus the 
background control level.  * p<0.05 
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Figure 2: VACV does not directly affect the RsL.11 or CTLL T cells.  (a) RsL.11 T cells 
were infected with VACV (MOI= 4) for 4 h and then incubated with decreasing numbers of 
antigen-pulsed PECs.  After 24-48 h, supernatants (50 µl) were collected and assayed for IL-2 
production using the CTLL IL-2 bioassay. (b) RsL.11 T lymphocytes were uninfected or infected 
for 3-4 h and then stimulated with PECs/50 nM GPMBP, 25 µg/ml Con A, or 100 nM PMA/2 
µM ionomycin. Supernatants (50 µl) were collected at 20- and 40-h and assayed for IL-2. (c) 
RsL.11 T cells were infected with VACV for 10 h, and growth metabolism was measured by 
reduction of 10 µl MTS/PMS and absorbance was read at 492 nm. (d) CTLL cells were infected 
with VACV (MOI=5) for 4 h and then placed in media with varying amounts of an IL-2-
containing supernatant.  Proliferation was measured by adding 10 µl MTS/PMS.   
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Figure 3: VACV infection and antigen concentration.  PECs were infected with VACV 
(MOI=2) for 4 h and then pulsed with a titration of GPMBP (50-250 nM) before being 
cocultured with antigen-specific T cells.  Supernatants (50 µl) were collected at 24- to 48-hpi and 
assayed for IL-2 using the CTLL IL-2 bioassay.  
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Figure 4: VACV infection and B cell antigen presentation. (a) 25,000 1153 B cells were 
infected for 6 h, and then pulsed with the HEL74-88 antigen for 1 h, followed by the addition of 
25,000 B04 T cells.  After a 24- to 48-h incubation, supernatants (50 µl) were collected and 
assayed for IL-2 using the CTLL IL-2 bioassay. (b) 25,000 B04 T cells were infected for 24 h.  
MTS/PMS was then added to measure metabolism.  * p < 0.01 
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Figure 5: VACV infection and antigen-independent NO production.  PEC (a) or RAW 264.7 
macrophages (b) were infected at an MOI of 1 for 4 h, and were then stimulated to produce NO 
by the addition of LPS, IFN-γ, or a combination of both.  Supernatants (50 µl) were collected at 
24-48 h and then assayed for NO production by the addition of Greiss reagent.  Absorbance was 
read at 540 nm.   * p<0.05 
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Figure 6: VACV reduces cytokine synthesis as a result of antigen presention.  PECs were 
harvested from Lewis rats, infected with VACV (MOI=2) for 5 h, pulsed with 50 nM guinea pig 
myelin basic protein (GPMBP), and then co-cultured with the cognate CD4+ RsL.11 T cell line.  
Supernatants (50 µl) were collected at 24 hpi and assayed for the production of cytokines using 
the LincoPlex 24 rat cytokine/chemokine Luminex bead immunoassay kit.  Interleukin (IL)-2 
and interferon (IFN)-α values were divided by 20 and 100 (hatch marks), respectively, to fit to 
scale.  * p < 0.05.   
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Figure 7: VACV decreases MHC class II expression.  PECs or 1153 B cells were infected 
with VACV for 5 h, washed, and incubated with no primary antibody (MFI for 1153: uninfected 
cells, 8.4 +/- 0.59; VACV-infected cells, 5.4 +/- 0.44; PEC: uninfected cells 2.35 +/- 0.06; 
VACV-infected cells 2.38 +/- 0.48), anti-class II MHC (MFI for uninfected cells, 145 +/- 13.4; 
VACV-infected cells, 76 +/- 2.8), or anti-CD45 and then fluorescein isothiocyanate (FITC)-
conjugated secondary antibody and analyzed by flow cytometry.   
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Figure 8: VACV inhibits the metabolism of macrophages.  PECs (a) were infected with 
VACV (MOI=2) and 1153 B cells (b) were infected at an MOI of 5, and metabolism was 
measured by the reduction of 10 µl of MTS/PMS.  Standard deviation bars are shown on all 
figures but are too small to be visible on some graphs.  * p < 0.05.   
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Figure 9: VACV induces apoptosis in macrophages.  PECs or RAW 264.7 macrophages were 
infected with VACV for 4 h (MOI=2).  1153 B cells were infected for at an MOI=5 for 6 h.  
Apoptosis was assessed by staining cells with annexin V-fluorescein isothiocyanate (FITC) and 
propidium iodide (PI) and analyzed by flow cytometry.  Variation was not higher than 2% 
between duplicate samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55  
 
 
 
 
 56  
Figure 10: VACV does not replicate to high titers in PECs.  BS-C-1 cells or PECs were 
infected with VACV (MOI=10).  Cells were collected at designated times post-infection.  Cell-
associated virus was titrated on BS-C-1 monolayers.  PFU, plaque-forming units. 
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Figure 11: VACV decreases peptide-MHC II complexes.  Spleens were harvested from 
B10.A-H2^i5 H2-T18^a/(5R)SgSnJ mice, and uninfected or VACV-infected with purified virus 
for 3 h (MOI=10), and then incubated with biotin-conjugated Y-Ae and streptavidin-RPE.  
C57BL/6 mice were used as a negative control and showed no staining above background.   
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Abstract 
 The VACV gene A35R (Copenhagen designation) is highly conserved in mammalian-
tropic poxviruses and is an important virulence factor, but its function was unknown.  We show 
herein that A35 does not affect viral infectivity, apoptosis induction, or replication; however, we 
found that A35 significantly inhibited MHC class II-restricted antigen presentation, immune 
priming of T lymphocytes, and subsequent chemokine and cytokine synthesis.  A35 localized to 
the endosomes and reduced the amount of a model antigenic peptide displayed in the cleft of 
class II MHC.  In addition, A35 decreased VACV-specific T cell responses in vivo.  Thus, this is 
the first report identifying a function for the A35 protein in virulence as well as the first report 
identifying a VACV gene that inhibits peptide antigen presentation.   
Introduction 
Poxviruses are large, double-stranded DNA viruses (~200 kb) that are capable of 
infecting a wide variety of animals (141).  The most infamous poxvirus is Variola virus, the 
causative agent of smallpox.  Smallpox is estimated to have killed over 500 million people in the 
20th century before it was declared eradicated by the World Health Organization in 1980 (124).  
Smallpox now presents itself as a danger in biowarfare and bioterrorism.  Other poxviruses can 
also cause significant disease in humans.  In 2003, a Monkeypox outbreak occurred in the United 
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States, infecting over 70 people (34).  Fortunately, this was an attenuated strain, and there were 
no human fatalities (34).  A widespread monkeypox outbreak would be more difficult to contain 
than smallpox, due to the fact that monkeypox can replicate and persist in animal reservoirs.  
Other emerging zoonotic poxviruses include buffalopox in Asia (100), tanapox in Africa, Europe 
and the United States (52, 198), cowpox in humans and primates (causing widespread fatalities) 
(129, 132, 197), and Cantagalo in South America (45).  Molluscum contagiosum virus is 
commonly seen in children and AIDS patients, accounts for nearly 300,000 doctor visits each 
year in the United States (140), and is emerging as a sexually transmitted disease.    
 The eradication of smallpox was the result of the most successful vaccination program in 
history. Routine vaccination was stopped in most countries in the early 1970’s due to the poor 
safety record of the vaccine, live VACV.  Vaccination is contraindicated for many individuals, 
including those who have inflammatory skin conditions, such as eczema, and those that are 
immunocompromised or pregnant (111).  In a recent vaccine trial, it was reported that 1 out of 
every 450 of those vaccinated had a serious adverse vaccine reaction (29), and vaccine trials 
were stopped after reports of increased adverse cardiac events following vaccination (60, 211).  
In recent years, attenuated and/or non-replicating VACV strains have been increasingly 
employed to reduce risks, and many VACV strains are being used as a platform in the 
development of vaccines for other diseases, such as HIV, malaria, and cancer (56, 177, 203, 
217).  Thus it is crucial to elucidate the virulence mechanisms in VACV and particularly those 
that interfere with the development of a robust immune response. An increased understanding of 
poxvirus pathogenesis will aid both in antiviral drug development and in the design of improved 
vaccines. 
While VACV elicits a strong immune response, it also encodes a plethora of 
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immunosuppressive genes and many of unknown function (213).  Gene 158 of VACV Western 
Reserve (WR) strain, commonly referred to as the A35 gene by the VACV Copenhagen 
designation, is highly conserved in mammalian-tropic poxviruses and vaccine strains (170, 213), 
but has no similarity to non-poxvirus proteins, giving no clues as to its function.  A mutant A35 
deletion virus (A35Δ) replicated normally in several tissue culture cell lines, but was highly 
attenuated (100-1000 fold) in the intranasal (i.n.) and intraperitoneal (i.p.) mouse challenge 
models (164, 170).  A rescue virus was constructed that returned the wild type A35 gene to the 
mutant, and this virus construct restored virulence, confirming that the viral phenotype mapped 
to the A35 locus.  While it is difficult to compare the virulence of various gene deletion mutants 
because many have not been tested in the intranasal model measuring weight loss (intracranial 
inoculations or measures of viral titers in organs have often been performed instead), available 
data in the i.n. model indicate that the A35Δ virus is more attenuated than the A46R deletion 
mutant (195), similar in virulence to the IL-18 binding protein knock out virus (159), slightly 
less attenuated than the thymidine kinase (TK) knock out (113), and less attenuated than the E3L 
deletion, which causes a 1000 fold attenuation (216).  The A35Δ virus produced similar 
quantities of the various morphogenic forms of virus compared to the parental wild type WR 
virus, with similar kinetics, and virus particles were similarly infectious on a per particle basis 
(170).  We showed that this gene encodes a non-glycosylated, non-secreted 23 kD protein 
expressed early during the virus life cycle, but its mechanism of action was unknown.  Here, we 
show that VACV A35 gene product blocks immune priming of T lymphocytes by interfering 
with MHC class II-restricted antigen presentation. 
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Materials and Methods 
Cells and Virus 
VACV Western Reserve (WR) strain and A35Δ mutant virus stocks were propagated 
using BS-C-1 cells as previously described (170).  For titrations of VACV, BS-C-1 monolayers 
were fixed and stained with 0.1% crystal violet in 20% ethanol.  All cells were grown in media 
containing 10% FBS.  CD4+ RsL-11 T cell clones were derived and maintained as previously 
described (127).  CTLL-2 (ATCC # TIB-214) were maintained in RPMI supplemented with 
0.4% IL-2-containing baculovirus supernatant (127).  RAW 264.7 (ATCC # TIB-71), a mouse 
macrophage cell line, was maintained in DMEM.  The mouse B cell line 1153 (kind gift from 
Janice Blum) was maintained in RPMI (116).   
Cell Tropism Replication 
The cell type of interest was split into two groups of equal number for infection.  One 
group was infected with WR and the other with A35Δ.  The cells were infected for 20 h at 
MOI=1 followed by three freeze/thaw cycles to release newly formed virus particles.  
Replication was measured by titering the cell lysates on a monolayer of BS-C-1 cells and 
counting the plaques that formed 40 h later. For early replication in mouse organs, groups of 
mice were intranasally challenged with WR (170) and A35Δ at 104 pfu/mouse, and nose, lungs, 
blood, brain and spleen were harvested on day 1, 2 and 3 (6 mice on each day) post challenge.  
Organs were freeze/thawed three times, homogenized, sonicated, and titered as above. 
Peritoneal Macrophage Isolation and Antigen Presentation Assays 
Lewis rats (bred and maintained at the AAALAC-certified Brody School of Medicine 
animal care facility at East Carolina University) were injected i.p. with 200 µg of inactivated C. 
parvum in 5 ml of HBSS.  Two to three days later, the rats were sacrificed and peritoneal exudate 
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cells (PEC) were harvested by washing the peritoneum in cold HBSS.  PEC (>95% CD45+ 
hematopoietic lineage) were infected for 5 h with either WR or A35Δ, and placed into 96-well 
plates.  PEC were incubated with 50 nM guinea pig myelin basic protein (GPMBP) for 30 
minutes, followed by addition of 25,000 Lewis rat CD4+ RsL.11 clones specific for GPMBP 
(127).  The antigen presentation plates were incubated for 24-48 h at 37ºC, 5.0% CO2. After 
incubation, 50 µl of supernatants were transferred into an empty 96-well plate and frozen for the 
following assays.  All animal experiments were in compliance with NIH guidelines. 
CTLL IL-2 Bioassay 
IL-2 was measured using previously described methods (127).  Briefly, 10,000 CTLL 
clones were washed, resuspended in RPMI, and added to the collected supernatants.  The plates 
were incubated for 48 h at 37ºC, 5.0% CO2, followed by the addition of 10 µl of MTS/PMS (2.0 
mg/mL MTS, Promega; and 0.1 mg/mL PMS, Sigma).  The absorbance was read at 492 nm.  
Media only was used to define the background control level and known IL-2 containing 
supernatants were used as positive control. 
NO Measurement 
50 µl of the harvested supernatants were transferred into a separate 96-well plate 
followed by the addition of 50 µl of Griess Reagent (1% sulfanilamide–0.1% N-[1-naphthy] 
ethylenediamine in 2.5% phosphoric acid) into each well.  The absorbance was read at 540 nm 
(27).   
Cytokine Measurement 
50 µl of the harvested supernatants were analyzed using the LincoPlex 24 Rat 
Cytokine/Chemokine Luminex Bead Immunoassay Kit according to the manufacturer’s 
instructions (Linco Research).  The supernatants were incubated with a panel of anti-cytokine 
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antibodies immobilized on Luminex beads (Bio-Rad Laboratories).  The following cytokines 
were analyzed: IL-1α, IL-1β, IL-2, IL-6, IL-17, IL-18, MIP-1α, GM-CSF, IFN-α, growth 
regulated oncogene alpha/keratinocyte attractant (GRO/KC), RANTES, TNF- α, MCP-1, 
eotaxin, G-CSF, IL-4, IL-9, IL-13, IL-5, and IL-10.  Reagents for IFNγ were not available at the 
time.  Samples were run according to the manufacturer’s instructions (Bio-Rad) and analyzed on 
the BioPlex protein array reader (Bio-Rad) in the Duke University Human Vaccine Institute 
Immune Reconstitution Core Facility (Durham, NC).           
RsL-11 Stimulation Assay 
CD4+ RsL.11 T lymphocytes were washed and resuspended in RPMI.  The cells were 
infected for 3-4 h, plated in a 96-well format, and stimulated with PEC pulsed with 50 nM 
GPMBP, 25 µg/ml Con A (Sigma), or 100 nM PMA/2 µM ionomycin (Sigma).  The plates were 
incubated at 37o C, 5% CO2.  50 µl of the harvested supernatants were collected at 20- and 40-h 
and assayed for IL-2 using the CTLL bioassay already described. 
Metabolism/Survival Assays 
Cells of interest were infected with VACV (MOI=2). Metabolism was measured by the 
addition of 10 µl MTS/PMS 4-24 hpi, and analyzed similarly to the method described above for 
the CTLL IL-2 Bioassay.  Absorbance was read at 492 nm at various times post infection. 
Tetrazolium salts such as MTS are reduced to colored formazan products during cellular 
respiration.  As only live cells respire, the MTS assay can be used to measure cell survival. 
Flow Cytometry  
Cells were infected for 4 hours and then washed in cold PBS containing 1% heat-
inactivated FBS and 0.1% sodium azide.  3 x 105 cells were stained with an anti-MHC II 
concentrated supernatant (Y3P, AF6120, and MKS4), OX1 anti-CD45, or human anti VACV 
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(Cangene VIG) for 1 h on ice, washed once, and then incubated with a FITC-conjugated goat 
anti-mouse IgG (Southern Biotech) or anti human-phycoerythrin (PE). For measurement of 
apoptosis, cells were infected and then stained with annexinV-FITC/propidium iodide (PI) (BD 
Pharmingen) per the manufacturer’s instructions.  Expression was measured using a FACScan 
(Becton Dickinson) and analyzed with Cell Quest software.     
Peptide-MHC Association 
The Y-Ae antibody specifically detects a complex of peptide 52-68 from I-Ed MHC class 
II bound in the cleft of MHC class II I-Ab (84, 173).  This complex is formed in mice that 
express both alleles. Spleens were harvested from B10.A-H2^i5 H2-T18^a/(5R)SgSnJ mice 
(Jackson Labs); C57BL/6 mice were used as a negative control.  Unfractionated splenocytes 
were infected with sucrose gradient purified virus for 3 h (MOI=10) and then incubated with 
biotin-conjugated Y-Ae (eBioscience).  Cells were washed and incubated with streptavidin-RPE 
(Southern Biotech). Goat polyclonal IgG antibody to CLIP (P-15, Santa Cruz) and donkey anti-
goat IgG FITC (Jackson Labs) were used to measure CLIP peptide bound in MHC class II on the 
surface of cells. Samples were analyzed using a FACScan equipped with Cell Quest software. 
Immunofluorescence Microscopy 
PEC were harvested as described above and grown on coverslips for 4 h.  The cells were 
then infected at an MOI=10 for 2 h, fixed and permeabilized in 3% paraformadehyde and 0.1% 
Triton X-100, respectively, and then stained with a rabbit anti-A35 antibody 1:4000 (170) and 
one of the following polyclonal goat anti-endosome antibodies (Santa Cruz Biotechnology) at 
1:80 diluted in 0.1% Triton X-100/PBS: Lamp-1 (C-20), Rab 7 (A-16), Rab 5B (C-12), or RhoB 
(M-19).  The coverslips were then washed and incubated with Alexa Fluor 633 (Invitrogen) and 
a FITC-conjugated anti-rabbit IgG (Sigma) for 45 m, followed by a final round of washes.  The 
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cells were visualized with a Zeiss confocal microscope and pictures were taken with the 100x 
objective. 
One-Step Growth Curve 
A one-step growth curve was performed as previously described (170). 
IFNγ  Elispot 
To enumerate cells secreting IFNγ , 96-well ELISA plates (Immulon H2B Thermo 
Electron) were coated overnight with rat anti-mouse IFNγ  (1 mg/ml Pharmingen).  Plates were 
washed with blocking buffer (PBS 1% FBS) before adding murine splenocytes in RPMI 1640. 
Stimulation of splenocytes was achieved by the addition of virus (MOI=2) followed by 
incubation for 40 h at 37°C.  Plates were then washed and incubated with 0.4 µl biotinylated rat 
anti-mouse IFNγ  (Pharmingen 0.5 mg/ml).  Plates were washed and incubated with streptavidin 
AP for 1 hr at 37°C.  Plates were developed with agarose/BCIP/AMP buffer mixture.  Spots 
were counted using a dissection microscope.  
Statistical Analysis 
Experiments were repeated at least three times and representative data are shown.  A two-
tailed Student’s t test was used to compare groups.  p values < 0.05 were considered significant.    
Results 
A35 Effects on Replication 
We have shown previously that the A35Δ virus is attenuated in a mouse challenge model, 
but that the mutant virus replicated and spread similar to the WR parental strain in eight cell lines 
(RK-13, HeLa, CV-1, BS-C-1, A549, MRC-5, TK-, BHK-21) derived from human, rabbit, 
monkey and hamster (170).  Still it was possible that the A35Δ was attenuated in vivo because 
the A35 gene was required for replication in certain cell types or tissues, such as immune cells, 
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neural tissue (since the VACV-WR strain is neurovirulent) (186), or heart because VACV causes 
cardiac inflammation (7, 60).  Various cell preparations listed below (or BS-C-1 cells as control 
permissive cells) (170) were infected with WR or A35Δ mutant at an MOI of 1 for 1 day, and 
then virus titers were measured.  The presence of the A35 gene in WR did not reproducibly 
enhance viral replication more than 2 fold relative to the A35Δ in any of the cells or tissues 
tested, including: Lewis Rat Peritoneal Exudate Cells (PEC), splenocytes from a young and old 
rat, rat thymocytes, activated and resting RSL-11 T-cells, R1-T T-cells, rat alveolar macrophage 
line NR8383, mouse CTLL, PC-12 neuronal cells (NGF-differentiated and undifferentiated 
morphologies), Heldtilt Mouse primary brain and heart cell suspensions, human fetal fibroblasts, 
and HEK (human kidney line) cells (data not shown).  We also assessed the effects of A35 on 
early replication in tissues of mice i.n. challenged with WR and A35Δ at 104 pfu/mouse (170), 
and found no significant difference in replication in nose, lungs, blood, brain and spleen on days 
1, 2 and 3 post challenge. Thus, there was no evidence for A35 involvement in host range or 
tissue tropism, suggesting that A35 is not required for any steps in replication, morphogenesis, or 
spread of virus. 
A35 Inhibits IL-2 and NO Production 
Because the A35 gene was not required for replication but did affect virulence in vivo, we 
suspected that A35 might be involved in regulating aspects of the host immune response.  To test 
this hypothesis, we used a model in vitro MHC class II-restricted antigen presentation system 
(127) and measured responses of both the T lymphocytes and the macrophage APC.  Rats are 
naturally infected with orthopoxviruses (129), and rat peritoneal exudate cells (PEC) are a rich 
source of normal primary macrophage.  PEC were infected in triplicate with WR virus or the 
A35Δ virus, pulsed with antigen (guinea pig myelin basic protein, GPMBP), and incubated in 
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varying numbers with a cognate CD4+ T cell line, RsL.11 (127).  Supernatants were collected, 
and IL-2 production was determined as a measure of the T cell response to the antigen 
presentation.  T cells in the uninfected groups were able to secrete more IL-2 than either the T 
cells in the A35Δ-infected or the WR-infected groups (Fig 12a).  The WR-infected PECs caused 
the T-cells to secrete significantly (p < 0.05) less IL-2 than A35Δ-infected cells 15-72 hpi, 
indicating that A35 down-regulates MHC class II-restricted antigen presentation responses in 
vitro.  A similar A35-mediated down-regulation of IL-2 production was observed when resting 
PECs and unfractionated rat splenocytes were used as APC (data not shown).  No IL-2 was 
produced in the absence of antigen or either cell type indicating that IL-2 production is a specific 
response to antigen presentation.   
Since production of IL-2 is a measure of the T cell response, we also wanted to measure 
nitric oxide (NO), which is produced by the macrophage and has been shown to be an important 
anti-viral defense (94, 123).  NO production was measured in supernatants collected from the in 
vitro antigen presentation system described above. Upon antigen presentation stimulation, 
uninfected macrophages produced significantly more NO than infected cells, while WR-infected 
macrophages produced significantly (p < 0.05) less NO than the A35Δ-infected macrophages 
(Fig 12b). NO was not produced in the absence of antigen or either cell type indicating that this 
is a specific antigen presentation response.  These data indicate that A35 inhibits both the T 
lymphocyte and APC responses to antigen presentation.  
A35 Reduces Cytokine Responses Induced By Antigen Presentation 
We next wanted to determine whether A35 specifically reduced the amount of IL-2 and 
NO produced as the result of antigen presentation (Fig 12), or if the presence of A35 in WR 
broadly affected cytokine responses.  Similar to experiments above, PEC were infected in 
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triplicate with WR or A35Δ, pulsed with antigen, and added to RsL.11 T cells.   Supernatant 
cytokines were measured using an antibody-bead-based fluorescent assay.  Results showed a 
broad and significant reduction in multiple cytokines and chemokines (Fig 13). The A35Δ virus 
evoked significantly (p < 0.05) higher levels of MIP1α, IL-1β, GMCSF, IL-1α, IL-2 (confirming 
our previous IL-2 bioassay results), IFN-α, 1L-17, GRO/KC, RANTES, and TNFα, (but not IL-
18) than WR, suggesting that the presence of A35 inhibits production of these cytokines and 
chemokines and generally dampens all antigen presentation-induced responses.  
A35 Does Not Affect the RsL.11 or CTLL T Cells Directly 
In the antigen presentation experiments described above, PEC were pre-infected prior to 
addition of antigen or T cells.  However, it remained possible that the T cells also became 
infected during the co-incubation, as some T cells can be infected by VACV (30, 175).  To 
determine if VACV and A35 had any direct effects on the responding T cells, we performed a 
similar assay but with infected T cells and uninfected PEC.  We determined if VACV and A35 
affected the ability of the RsL.11 T cell to produce IL-2.  RsL.11 T cells were incubated with 
either WR or A35Δ for 3 h, washed, and then incubated with a titration of uninfected antigen-
pulsed PEC.  Supernatants were harvested 24-48 hpi, similar to experiments in Fig 12 and 13, 
and tested for IL-2.  Infection with either virus did not significantly affect the response of the T 
cell compared to uninfected T cells (Fig 14a).  We also found that VACV did not affect RsL.11 
responses to mitogen (ConA) or chemical stimulation (PMA/ionomycin) (Fig 14b). 
 We next wanted to assess whether RsL.11 T cells were permissive to VACV infection.  
We incubated VACV with the known permissive cell line, BS-C-1, and RsL.11 T cells.  Levels 
of infectious virus increased 2 logs in the BS-C-1 culture but did not increase in the RsL.11 T 
cell culture (data not shown), and infection had no significant effect on cellular metabolism up to 
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64 hpi (Fig 14c). Together these data indicate that the RsL.11 T cells are refractory to VACV 
infection.  
 To assess viral affects on the CTLL cells used in the IL-2 bioassay, CTLL were incubated 
with WR or A35Δ for 5 h and then placed in IL-2-containing media to stimulate their 
proliferation.  IL-2 increased the response of the uninfected CTLL compared to media containing 
no IL-2, and VACV did not significantly alter this response up to 48 hpi (Fig 14d).  These data 
suggest that VACV (with or without the A35 gene) has little effect on either the RsL.11 or CTLL 
under these assay conditions and that A35 exerts its influence directly on the APC instead.  In 
order to further test this hypothesis, we performed an experiment using a paraformaldehyde fixed 
infected human B cell line to present antigen in triplicate as previously described (116).  WR 
infected (MOI=10) fixed B cells presented 30% as well as uninfected fixed B cells, and 
significantly less than the A35Δ infected fixed B cells, which presented 68% of the levels of 
uninfected fixed B cells.  These data mirror what we have seen in the rodent system using 
unfixed antigen presenting cells where A35 potentiates VACV inhibition of antigen presentation.  
Together these data indicate that the APC are directly affected by A35 prior to interaction with T 
cells.  Thus we further explored the effects of A35 on APC. 
A35Δ  is as Infectious as WR Virus 
We had previously shown that A35Δ mutant virus particles were equally infectious on a 
per particle basis as wild type WR parental virus (170) in BS-C-1 cells, however it was possible 
that the A35Δ virus infected immune cells (PEC) less well than the wild type, thus allowing WR 
to be more inhibitory.  In order to assess viral infectivity in these cells, PECs were incubated 
with WR and A35Δ for 10 h, and viral antigens were measured by FACS analysis using a human 
polyclonal anti-VACV hyperimmune serum.  In three experiments, the A35Δ showed as much 
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viral antigen staining as wild type virus (Fig 15a), indicating that the A35Δ is as infectious as 
wild type virus in these cells and proceeds normally through viral protein expression up to 10 
hpi.  Uninfected cells stained with anti-VACV hyperimmune serum and VACV infected cells 
stained with secondary antibody alone gave comparable negative results.   
A35Δ  Replicates Equal to WR in PECs 
We also assessed the replication of both viruses in PEC using a one-step growth curve.  
We infected PEC and BS-C-1, a known permissive cell line, with WR or A35Δ, and harvested 
supernatants and cells for titers at various time points. WR and A35Δ were able to replicate 
similarly in BS-C-1 cells increasing approximately 2 logs by 30 hpi (Fig 15b), while neither 
virus replicated well in PEC.  We also measured virus released into supernatants (not shown), 
and showed that WR and A35Δ had very similar supernatant titers.  These data indicate that A35 
does not alter viral replication in PEC. 
A35 Does Not Induce Apoptosis of PEC 
One possible explanation for the A35 mediated reduction in antigen presentation was that 
A35 might reduce the viability of the APC since VACV is known to induce apoptosis in many 
APC types (22, 62, 80, 95).  To determine this, PEC were infected with WR or A35Δ, and 
metabolism/viability was measured.  While virus infection reduced metabolism/survival of both 
cell types by 24 hpi, there was no difference in metabolism between the WR- and A35Δ-infected 
groups, suggesting that A35 does not promote cell death (Fig 16a).  Similar experiments were 
carried out in the murine RAW 264.7 macrophage line, and similar results were obtained: VACV 
decreased metabolism of RAW, but A35 had no effect.  Apoptosis induction was also measured 
in PEC using annexin V and propidium iodide staining at 4, 6 and 28 hpi.  VACV infection 
induced apoptosis as previously reported, from 17% to 43% in Fig 16b, but A35 had no effect at 
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any time point measured, indicating that the A35-induced reduction in antigen presentation was 
not likely due to the increased induction of cell death.    
 A35 Does Not Affect Antigen-Independent NO Production 
Since A35 acts on APC, and A35 caused an inhibition of NO production by PEC in 
antigen presentation assays with T lymphocytes (Fig 12), we tested the effects of A35 on NO 
production in response to purified LPS and IFNγ in PEC and the murine RAW 264.7 
macrophage cell line.  We infected cells for 4 h with either WR or A35Δ, stimulated the cells 
with IFNγ, LPS, or both, and then measured NO production in supernatants 24 hpi.  NO was 
produced by uninfected PEC and RAW in response to each stimulus (Fig 17), and VACV 
infection significantly reduced the amount of NO produced as previously reported (13), however 
the presence of A35 had no effect on this outcome.  We performed this experiment with a higher 
MOI of 5 and a lower MOI of 1 to assess whether an A35 effect might be seen at lower virus 
infectious dose, but no effect could be detected.  Thus, A35 does not always decrease 
macrophage NO responses, but inhibits NO production specifically as the result of antigen 
presentation interactions with T cells (Fig 12). These data suggested that A35 specifically blocks 
the interaction between the PEC and the RsL.11. 
A35 and MHC Class II and B7.2 Expression on APC 
Since data suggested that A35 might block interactions between APC and T cells, we 
measured the effect of A35 on surface expression of B7.2/CD86 and MHC class II, proteins 
important in antigen presentation.   Several labs have now shown that VACV can inhibit MHC 
class II and CD86 expression on APC in vitro and in vivo under various conditions (62, 86, 95, 
116, 227).  PEC were infected for 4 h at an MOI of 10 and analyzed by flow cytometry.  
Uninfected PECs were 43% bright positive for MHC class II, A35Δ-infected PECs were 39% 
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and WR-infected PEC were 29% (data not shown), indicating that the A35 protein plays a role in 
inhibiting the highest expression of MHC II on the surface of PECs.  We also looked at how A35 
affected the MHC II expression on the 1153 murine B cell line.  Following a similar approach to 
that described for the PEC, uninfected 1153 B cells were 38% bright positive (arrow shown) for 
MHC II while WR-infected 1153 B cells were 15% (Fig 18), and A35Δ-infected cells were 23%, 
indicating that the presence of A35 in WR mildly reduced MHC II surface expression.  In the 
same experiments, there was no difference in CD45 (leukocyte common antigen) expression 
between the groups, indicating that VACV and the presence of the A35 gene mildly but 
specifically decrease MHC class II on the surface of APC.  CD28 stimulation through B7 is 
required for protection from poxvirus infection (65), and B7.2 expression was also measured. 
PEC and the mouse 1153 B cell line were infected at an MOI of 5 for 4 hours and incubated with 
primary antibodies that recognize B7.2/CD86 costimulatory molecules.  Surface expression of 
B7.2 costimulatory molecule was decreased from 16% in uninfected and A35Δ infected cells to 
10% in WR infected cells, but infection did not decrease surface expression of CD45. These data 
suggest that A35 may modestly downregulate surface proteins required for antigen presentation. 
A35 Decreases the Amount of Peptide Presented in MHC II 
One level of immune regulation, both in homeostasis and infection, lies in controlling the 
association of peptides with the MHC molecules that present them (82).  We next sought to 
determine whether A35 affected the association of peptides with MHC II on the cell surface.  To 
do this, we used the Y-Ae antibody, which specifically detects peptide 52-68 from I-Ed MHC 
class II bound in the cleft of mouse MHC class II I-Ab (84, 173).  MHC class II molecules 
frequently present self peptides from surface proteins that recirculate through endosomes and are 
degraded, similar to exogenous antigens that are internalized.  The Y-Ae antibody recognizes a 
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major determinant (approximately 12% of MHC molecules) in mice expressing both of these 
class II molecules (173, 200).  We measured the amount of peptide bound in the cleft of MHC 
class II on the surface of uninfected, WR and A35Δ infected spleen cells.  As Figure 19 shows, 
uninfected and A35Δ infected cells were 63% positive for class II MHC molecules complexed 
with this I-E peptide, while infection with WR reduced this to 30% 3 hpi, with only a slight 
decrease in MHC class II expression. These data indicate that A35 interferes specifically with the 
loading of this model peptide into the cleft of MHC class II molecules or expression of such 
molecules on the cell surface.  As surface expression of antigenic peptide was decreased by A35 
in this model system, we tested whether MHC class II bound to the remnant chaperone invariant 
chain peptide CLIP was transported to the cell surface.  CLIP peptide was detectable on 
approximately 14% of uninfected cells, 24% of A35Δ infected cells and 33% of WR infected 
cells (Fig 19) suggesting that A35 enhances the binding and/or transport of CLIP peptides and 
thus may interfere with presentation of a wide variety of naturally occurring MHC class II 
presented antigenic peptides.  
To determine whether A35 affects VACV stimulated immune responses to VACV 
antigenic peptides during natural infection, we infected groups of 5 mice with 1000 pfu VACV 
i.n. as previously described (170) and enumerated VACV specific IFN γ secreting spleen cells on 
day 8 post infection.  WR infected mice produced significantly fewer IFNγ secreting cells 
compared to A35Δ infected mice and produced significantly lower levels of VACV specific 
antibody, suggesting that A35 also acts in vivo to suppress immune responses to VACV (164).  
PBS-vaccinated mice and vaccinated mouse cells without virus stimulation were used as 
negative controls and produced no signal. 
 
 76  
A35 Localizes to the Endosomes 
Since MHC and B7 proteins recycle in endosomes, and MHC class II is loaded with 
peptides in the endosomes, we determined the intracellular localization of A35 in APCs.  We had 
published previously that A35 localizes intracellularly in viral factories in BS-C-1 fibroblast 
cells, in which there is no A35 phenotype (170).  Since our data suggest that A35 functions in 
APC early after infection, we determined the localization of A35 in PECs at a time point when 
an A35 phenotype is seen in antigen presentation.  PEC were infected with either WR or A35Δ, 
and A35 was visualized using fluorescent microscopy.  The presence of A35 in the WR-infected 
PEC could be seen as diffuse punctuate staining throughout the cell (Fig 20), which is consistent 
with the staining of endosomal structures, where many aspects of MHC II antigen processing and 
presentation occur.  In order to verify endosomal localization, we co-localized the A35 protein 
with known endosomal markers, Rab 5 (plasma membrane and early endosomes), Rho B 
(multivesicular bodies), Rab 7 (late endosomes)), and Lamp-1 (late endosomes and lysosomes) 
(33, 66, 119, 167).  A35 showed partial co-localization with these endosomal markers, although 
least with Rab 5 (Fig 20).  In each case there were endosomal structures that had both A35 and 
the marker (yellow colocalization), but also punctate staining for each antibody alone (green or 
red).  Thus, A35 localizes generally throughout the range of endosomes in the cell, but is not 
found in all endosomes and does not partition to any distinct endosomal type.  The presence of 
A35 in these structures suggests that A35 protein may interact with or affect proteins in 
endosomes including class II MHC, although further research is required to elucidate with which 
proteins A35 interacts specifically. 
Discussion 
 We showed previously that the VACV A35 gene is an important virulence factor, 
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increasing virulence by approximately 100-1000 fold (164, 170), but its function was unknown.  
We have shown here that the VACV A35 gene product is not required for replication in a variety 
of cell types and tissues in six different mammals.  Furthermore, A35 does not control early 
replication in mouse tissues on days 1-3 post infection before specific immunity develops.  
However, we have shown that A35 affects the development of specific immune responses in 
vitro, specifically acting on APC.  A35 contributes to VACV-induced reduction in MHC II 
antigen presentation (Fig 12) and subsequent cytokine synthesis (Fig 13) using primary 
macrophages as APC, even though the mutant virus was able to infect the APC as efficiently as 
wild type (Fig 15).  A35 did not affect metabolism, permissiveness, apoptosis of PEC nor NO 
production induced by immunostimulators in rat PEC or the murine RAW macrophage cell line.  
These data suggested that A35 did not have a major systemic effect on macrophage, but rather 
that it specifically interfered with the interaction between APC and T cells since those assays 
specifically showed an A35-dependent phenotype.   
We subsequently found that A35 mildly affected the expression of MHC class II on the 
surface of the APC (Fig 19).  While several labs have now shown that VACV can inhibit MHC 
class II and CD86 expression on APC in vitro and in vivo under various conditions, there has 
been much debate about the circumstances under which this regulation occurs and its 
significance (116). Some laboratories have associated the reduction in surface molecules with 
induction of apoptosis (95), while others have concluded that VACV does not block basal B7.2 
or class II MHC expression but that it blocks activation-induced B7.2 or class II MHC 
expression (62 2000).  We have found that early after infection, VACV and the A35 gene can 
mildly decrease expression of these surface markers both in rat PEC and in a murine B cell line.  
Whether a small decrease in MHC class II levels will have physiologic significance is unknown, 
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however it is known that MHC class II antigen presentation is crucial to protection from 
poxvirus infection.  In studies with knockout mice, it was found that the absence of MHC class I 
molecules or CD8 T cell response did not diminish protection but that decreases in CD4 or MHC 
class II expression caused a loss of protective immunity (221, 224). 
VACV genes B1R and H5R have been shown to inhibit CD1d-mediated non-classical 
lipid antigen presentation, although the importance of this function was difficult to ascertain 
because of the pleiotropic effects of these genes (220).  Several laboratories have shown that 
VACV also blocks MHC class II antigen presentation in a number of assays using different APC, 
model antigens (exogenous, virus encoded and cellular endogenous), and response measures 
(163). VACV-infected primary Langerhans cells were deficient in presenting KLH peptide to a 
cognate T cell line, as measured by production of IFNγ (51).  Primary rodent bone marrow 
derived macrophages infected with VACV were deficient in presenting lysozyme peptide to T 
cells, as measured by stimulation of IL-2 production (126).  Li et al found that VACV inhibited 
MHC class II antigen presentation in in vitro infected human and rodent APC, including B cell 
lines, dendritic cells, macrophage and fibroblasts presenting several antigens (116).  The 
accumulation of data indicates that VACV generally inhibits MHC class II antigen presentation; 
however, no viral gene had previously been identified as blocking antigen presentation.     We 
have shown here that A35 interferes with antigen presentation responses to an exogenous model 
antigen (Fig 12, 13), as well as surface expression of an endogenous peptide in MHC class II 
(Fig 19).   We have also found that A35 increases surface CLIP expression in MHC class II 
suggesting that A35 may inhibit presentation of a range of antigenic peptides.   Further, we have 
found that A35 diminishes anti-VACV T cell responses and antibody in mice (164) suggesting 
that A35 may similarly inhibit presentation of virally expressed VACV antigens during infection 
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in vivo.   
Our data suggest that VACV A35 contributes to viral inhibition of MHC class II antigen 
presentation by decreasing the expression of antigenic peptides in the cleft of MHC class II on 
the surface of infected cells.  We showed this in the murine system with an MHC derived peptide 
as the antigen.  Dr. Blum’s laboratory showed that VACV decreases the amount of glutamate 
decarboxylase (GAD) peptide in the cleft of MHC class II in a human B cell line (116).  
Together these data suggest that VACV inhibition of peptide loading into the cleft is a general 
mechanism of immune response inhibition independent of the antigen or APC type.  The fact that 
A35 is very highly conserved in mammalian tropic poxviruses suggests that A35 may act 
similarly in a number of different viruses and host species. Interestingly, Fig 19 shows that there 
is a population of cells in spleens that is unaffected by the presence of VACV and A35 gene 
(MOI of 10).  Since splenocytes contain numerous cell types, these data suggest that there is a 
VACV resistant population in the spleen, consistent with other studies showing differing 
sensitivities to infection among immune cells (30, 175).  It will also be important to determine 
the effects of A35 on lymphocytes in the target organs, especially the lungs.   
In these experiments, we showed that A35 inhibited antigen presentation, suggesting that 
the A35Δ mutant viruses will provide improved vaccines, as well as improved platform vaccines 
for other infectious diseases and cancer treatment.  The A35 gene is conserved in all VACV 
vaccine strains including MVA.  While A35 inhibited antigen presentation, it was also clear that 
the A35 deletion mutant virus blocked antigen presentation when compared to uninfected APC 
(Fig 12, 13).  This suggests that there are multiple poxvirus proteins that function independently 
to decrease antigen presentation.  It is important to identify these immunosuppressive genes and 
test the cognate knockout viruses as improved poxvirus (or poxvirus platform) vaccines. 
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While we showed that both T cell and PEC cytokine production was reduced subsequent 
to antigen presentation interactions, our data indicated that it was the APC that were directly 
affected by VACV, and the T cells were indirectly affected via regulation of the APC. A35 had 
the effect of suppressing the production of numerous cytokines and chemokines, which are 
crucial in the development of an appropriate immune response.  Notably, many of the cytokines 
that are regulated by VACV and A35 are chemotactic factors (MIP-1α, IL-1, TNF-α, GRO/KC, 
RANTES, and MCP-1), which aid in the migration of immune response cells to sites of 
inflammation and infection.  Interestingly, IL-18 was not significantly reduced by VACV and 
A35 (Fig 13).  Perhaps this is because IL-18 is stored intracellularly as pro-IL-18 and rapidly 
released upon stimulation (69).  Since IL-18 is an important factor in the induction of anti-viral 
IFNγ production, its storage for rapid release may be an evolved host mechanism to contravene 
immunomodulation by viral gene products such as A35.  The importance of IL-18 in antiviral 
defense is underscored by the possession of an IL-18 binding protein encoded by poxviruses 
(159). 
 There are multiple mechanisms by which A35 could decrease MHC II peptide 
presentation that must be further explored.  Future experiments will address with which cellular 
proteins A35 interacts.  Since A35 may affect peptide loading, it is possible that it interacts with 
invariant chain (Ii) that chaperones MHC class II proteins, directly with MHC class II itself, or 
DM molecules that are involved in the exchange of antigenic peptides.  Furthermore, we will test 
various immune responses to the A35Δ mutant virus in comparison to wild type virus in 
transgenic mouse models to understand which pathways are inhibited by A35.  Our hypothesis is 
that A35 acts through blocking MHC class II antigen presentation, and we predict that anti-viral 
CD4 responses will be diminished, and that this decrease in T helper cells will diminish 
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development of most downstream anti-viral effector cells (including CD8 cytotoxic T cells, and 
antibody secreting B cells).    Thus far our animal model data are consistent with this hypothesis, 
showing a reduction in both VACV specific antibody and splenic T lymphocyte responses (164).  
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Figures 
Figure 12: A35 inhibits the amount of antigen presentation-induced IL-2 and NO.  PEC 
were isolated from a rat, infected with VACV (MOI=2) for 5 h, pulsed for 30 min with 50 nM 
GPMBP, and then incubated with the cognate CD4+ RsL.11 T cell line.  Uninfected PEC served 
as a control.  At 24- to 48-hpi, supernatants (50 µl) were collected and assayed for either IL-2 
using the IL-2 dependent cell line CTLL (a) or for NO using Greiss reagent (b). For the CTLL 
bioassay, media only was used to define the background control level and known IL-2 containing 
supernatants were used as positive control. IL-2 production was determined as the mean OD 
value of the experimental group minus the background control level.  * p < 0.05 
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Figure 13: A35 reduces antigen presentation-induced cytokine synthesis.  PEC were 
harvested from Lewis rats, infected with WR or A35Δ virus (MOI=2) for 5 h, pulsed with 50 nM 
GPMBP, and then co-cultured with the cognate CD4+ RsL.11 T cell line.  Supernatants (50 µl) 
were collected at 24-h post incubation and assayed for the production of cytokines using the 
LincoPlex 24 Rat Cytokine/Chemokine Luminex Bead Immunoassay Kit. IL-2 and IFNα values 
were divided by 20 and 100 respectively to fit to scale. IL-6, IL-18, and MCP-1 were not 
significantly reduced by the presence of the A35 gene in WR, all other differences between WR 
and A35Δ were p < 0.05.  
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Figure 14: A35 does not directly affect T lymphocytes. (a) RsL.11 T cells were infected with 
WR or A35Δ virus (MOI= 4) for 4 h and then incubated with decreasing numbers of antigen-
pulsed PEC.  After 24-48 h, supernatants (50 µl) were collected and assayed for IL-2 production 
using the CTLL IL-2 bioassay. (b) RsL.11 T lymphocytes were infected for 3-4 h and then 
stimulated with PEC/50 nM GPMBP, 25 µg/ml Con A, or 100 nM PMA/2 µM ionomycin. 
Supernatants (50 µl) were collected at 20- and 40-h and assayed for IL-2. (c) RsL.11 T cells were 
infected with VACV for 10 h, and growth metabolism was measured by reduction of 10 µl 
MTS/PMS. (d) CTLL cells were infected with VACV (MOI=5) for 4 h and then placed in media 
with varying amounts of an IL-2-containing supernatant.  Proliferation was measured by adding 
10 µl MTS/PMS.  
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Figure 15: A35Δ  mutant virus is as infectious as WR and replicates equally.  a) PEC were 
incubated with WR and A35Δ at an MOI of 10 for 10 h, fixed, permeabilized, and incubated with 
human polyclonal anti-VACV hyperimmune sera.  Viral antigens were measured by flow 
cytometry.   b)  BS-C-1 cells or PEC were infected with either WR or A35Δ mutant virus 
(MOI=10).  Cells were collected at designated times post-infection and cell-associated virus was 
measured. 
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Figure 16: A35 and apoptosis.  (a) PEC were infected with A35Δ or VACV WR (MOI=2) and 
metabolism was measured by the reduction of 10 µl MTS/PMS.  (c) PEC apoptosis was 
measured using annexin V and propidium iodide and flow cytometry following a 4 h infection. 
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Figure 17: A35 does not block antigen-independent NO production. PEC (a) or RAW 264.7 
macrophages (b) were infected at an MOI of 1 for 4 h, and were stimulated with LPS, IFN-γ, or a 
combination.  Supernatants (50 µl) were collected at 24-48 h and then assayed for NO 
production.  
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Figure 18: A35 decreases MHC class II expression. 1153 B cells were infected with WR or 
A35Δ virus for 5 h, washed and incubated with no primary antibody, anti-class II MHC, or anti 
CD45 and then FITC-conjugated secondary and analyzed by flow cytometry.  Mean fluorescence 
intensities (MFI) for MHC class II were: UN 154, A35Δ 111, and WR 77. 
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Figure 19: A35 decreases peptide-MHC class II complexes.  Splenocytes from B10.A-H2^i5 
H2-T18^a/(5R)SgSnJ mice (Jackson Labs) were infected for 3 h at an MOI=10, washed, and 
then incubated with no primary antibody, antibodies to MHC class II or CLIP, or biotin-
conjugated Y-Ae anti-peptide in MHC antibody followed by streptavidin-RPE.  Samples were 
analyzed by flow cytometry, and MFI for Y-Ae were: UN 85, A35Δ 76, and WR 36.  MFI for 
CLIP were UN 5.7, A35 Δ 8.2, and WR 13.9. 
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Figure 20: A35 localization in PEC.  PEC were grown on coverslips for 4 h and then infected 
with WR or A35Δ virus at an MOI=10 for 2 h.  The cells were then fixed and permeabilized, and 
stained with a rabbit anti-A35 antibody and one of the following: goat anti-LAMP, goat anti-
Rab7, goat anti-RhoB, goat anti-Rab7.  The A35 protein was visualized with a FITC-conjugated 
secondary antibody, and the endosomal markers were visualized with Alexa Fluor 633.  
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Abstract 
 It has been shown previously that the highly conserved VACV A35 gene is an important 
virulence factor in respiratory infection of mice.  We show here that A35 is also required for full 
virulence by the intraperitoneal route of infection.  A virus mutant in which the A35 gene has 
been removed replicated normally and elicited improved antibody, IFNγ-secreting cell and 
cytotoxic T lymphocyte responses compared to wild type virus, suggesting that A35 increases 
poxvirus virulence by immunomodulation.  The enhanced immune response correlated with 
improved control of viral titers in target organs after the development of the specific immune 
response.  Finally, the A35 deletion mutant virus also provided protection from lethal challenge 
(1000 x LD50) equal to that of the wild type virus.  Together these data suggest that A35 deletion 
viruses will make safer and more efficacious vaccines for poxviruses.  In addition, the A35 
deletion viruses will serve as improved platform vectors for other infectious diseases and cancer 
and will be superior vaccine choices for post-exposure poxvirus vaccination as they provide 
improved kinetics of the immune response. 
Introduction 
Poxviruses are large, complex viruses with a broad host range and worldwide distribution 
(141).  Members of the family Poxviridae include Variola virus, the causative agent of smallpox, 
which induced a fatality rate of approximately 30% and killed hundreds of millions of people 
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before its eradication in 1980 (124).  Currently the most dangerous extant human-infecting 
poxvirus is monkeypox virus, which is commonly found in African rodents. Monkeypox virus 
causes a smallpox-like illness with a 10% fatality rate.  A recent study showed that 1.7% of 
people in the Likouala region in Africa had monkeypox specific IgM, indicating a significant 
ongoing infection rate (112).  An outbreak of a low virulence strain of monkeypox occurred in 
the United States in 2003, causing more than 80 human infections and several hospitalizations 
(34).  This outbreak raises concern that monkeypox virus could establish itself in wild rodent 
populations in North America (152), thus creating a local zoonotic reservoir for this emerging 
pathogen.  Of further concern are the facts that monkeypox is spreading more efficiently in 
humans, (81, 110, 144) and that the current poxvirus vaccine is not universally protective against 
monkeypox infection (117).   Both Variola and monkeypox viruses are considered bioterrorism 
and biowarfare concerns and are Category A select-agent pathogens.  There are also other 
poxvirus infections that sporadically cause human outbreaks, including Cantagalo in South 
America (45, 185), buffalopox virus in India (100), and incidence of Tanapox appears to be 
increasing (52, 198).  Molluscum contagiosum poxvirus accounts for approximately 300,000 
doctor visits each year in the United States alone (140).  Thus, the study of virulence 
mechanisms in this group of viruses is important.   
The eradication of smallpox was accomplished through the use of the related VACV as a 
live virus vaccine.  Despite its phenomenal success, the public vaccination program was 
discontinued because of the high incidence of complications due to the virulence of wild type 
VACV. It is estimated that approximately 25% of the population should not receive this vaccine 
because of immunodeficiency, eczema, pregnancy, or heart disease (60, 96, 211).  Safer vaccines 
are necessary to protect against emerging or released poxviruses.   In addition, poxviruses are 
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being used as platform vaccines for other diseases, such as human immunodeficiency virus, 
malaria, and cancer, because they induce a robust immune response and accommodate the 
insertion of large pieces of foreign DNA.  It is therefore of great importance to identify poxvirus 
virulence genes in order to develop safer and more effective poxvirus vaccines. Replication-
defective strains, such as Modified Vaccinia Ankara (MVA), have been used in an effort to 
reduce the risks associated with vaccination (41, 221), but production of these viruses can be 
challenging, they require higher doses of vaccine, and their protective efficacy against poxvirus 
infections in humans is unknown.  As poxviruses inhibit activation of antigen presenting cells 
and antigen presentation (116, 163), another way to construct a safer vaccine is to develop 
replication-competent vaccine strains that exclude immunosuppressive genes (19) while 
retaining protective antigenic epitopes (79, 148).  We show herein that the A35 gene is an 
excellent candidate for removal from vaccine strains.   
The VACV A35 gene is highly conserved in mammalian-tropic poxviruses, and a 
sequence identity search has revealed that the protein has little similarity to any other poxvirus 
protein or any non-poxvirus protein, suggesting that this gene has an important and novel 
function (170).  We have shown that the A35 gene is not required for viral replication in vitro, 
but is required for full virulence in the mouse model (170). We therefore tested the effects of 
A35R on immune responses during infection in the mouse model, and tested its protective 
efficacy against virulent challenge.  
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Materials and Methods 
Cells and Virus 
VACV Western Reserve (WR) strain and A35Δ mutant virus stocks were propagated 
using BS-C-1 cells in MEM containing 10% FBS as previously described (170).  P815 cells 
(ATCC) were grown in Dulbecco’s modified Eagle’s medium (DMEM).  
Mouse Infection and Sample Collection 
Four 5-week old BALB/c mice were anesthetized using isoflurane and infected 
intranasally (i.n.) as previously described (170) with purified virus in 18 µl (100 µl for i.p. 
infection), or mock infected with PBS. Titers were confirmed each experiment using the dilution 
used to infect mice that day.  Mice were weighed and monitored daily for signs of illness and 
were euthanized if 20% weight loss occurred.  For experiments assessing immune responses, five 
mice from each group were sacrificed, and the spleens were collected in ice cold RPMI medium.  
Splenocytes were obtained as previously described and incubated in RPMI (36).  Blood was 
collected using cardiac puncture, followed by centrifugation to separate plasma from red blood 
cells.  All experimental protocols were approved by the Animal Care and Use Committee of East 
Carolina University. 
ELISA 
To determine antibody response, 96-well ELISA plates (Immulon H2B Thermo Electron) 
were coated overnight with 0.1 µl/well (100 µl) crude WR virus in ELISA coating buffer (10.3 g 
H2BO4, 7.31 g NaCl, 1 L double distilled H2O, pH 8.5) at 4°C. Plates were blocked with 1% 
FBS/PBS at room temperature for 30 min. Plates were washed with ELISA wash buffer (1x PBS, 
0.02% Tween 20, 0.1% NaN3) and a titration of mouse sera was added. Plates were incubated at 
room temperature for 2 h and washed. Goat anti-mouse IgG-alkaline phosphatase (Southern 
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Biotech) was added and incubated at room temperature for 1 h. Plates were washed three times, 
developed (BioRad Alkaline Phosphate Substrate Kit) and absorbance was read at 405 nm.  Anti-
B5R ELISAs were similarly performed by coating plates with purified baculovirus-expressed 
B5R protein prepared by C-PERL (the kind gift of Stuart Isaacs). 
Measurement of Neutralizing Antibody 
VACV-specific neutralizing antibody was measured by incubating 25 µl of sera from 
PBS, WR or A35Δ-infected mice (n=5 ) with WR virus (200 pfu) in 100 µl of media containing 
10% heat inactivated FBS for 1 h on ice.  The virus/serum mixture was then added to confluent 
monolayers of BS-C-1 cells, and plaques were counted 40 h later.        
IFNγ  Enzyme-Linked Immunospot Assay (Elispot) 
Numbers of IFNγ secreting spleen cells were enumerated similarly to methods described 
previously (42, 70, 180). Ninety six-well plates (Immulon H2B Thermo Electron) were coated 
overnight with 0.2 µl anti-mouse IFNγ (1 mg/ml Pharmingen) at 4°C.  Plates were washed with 
blocking buffer before adding a titration of murine splenocytes in RPMI 1640 medium. 
Stimulation of splenocytes was achieved by either the addition of WR virus only (MOI=2) or 
with the use of 50,000 WR-infected (MOI=3) P815 stimulator cells, followed by incubation for 
40 h at 37°C.  Plates were then washed and incubated with 0.4 µl biotinylated rat anti-mouse 
IFNγ (Pharmingen 0.5 mg/ml) for 2 h at 37°C.  Plates were washed again and incubated with 
streptavidin-alkaline phosphatase (AP) for 1 h at 37°C.  Plates were developed with agarose-
BCIP (5-bromo-4-chloro-3-indolylphospahte)-AMP mixture, and spots were counted using a 
dissecting microscope.   
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CTL Assay 
Cytotoxic T lymphocyte (CTL) activity was measured as the release of lactate 
dehydrogenase (LDH) into supernatants from WR virus-infected P815 cells using Promega 
Cytotox kit.  P815 target cells were infected (MOI=5) for 3 h and added to a titration of 
splenocytes from the vaccinated mice in round-bottom 96-well plates at 37o C.  After 6 h, 50 µl 
of supernatant were collected and assayed for LDH by adding an equal volume of substrate and 
reading the absorbance at 492 nm. Incubation of splenocytes with uninfected P815 cells was 
used to measure non-specific lysis, which was subtracted from each experimental group to yield 
specific lysis. 
Cytokine Measurement 
Sera were analyzed using the LincoPlex Mouse Cytokine/Chemokine Luminex bead 
immunoassay kit according to the manufacturer’s instructions (Linco Research).  Sera were 
incubated with a panel of anti-cytokine antibodies immobilized on Luminex beads (murine 23-
plex, Bio-Rad Laboratories), run according to the manufacturer’s instructions, and analyzed on 
the BioPlex protein array reader (Bio-Rad) at the Duke University Human Vaccine Institute 
Immune Reconstitution Core Facility (Durham, NC).           
Virus Titrations 
Groups of mice (n=5) were sacrificed at various days post infection (dpi), and the organs 
were placed into 1 ml of ice cold RPMI medium.  The organs were then freeze/thawed three 
times, homogenized, and sonicated.  Viral replication was evaluated by titration of the organ on 
BS-C-1 monolayers and staining with 0.1% crystal violet in 20% ethanol 40 h later. 
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Statistical Analysis 
Experiments were repeated at least three times and representative data are shown.  A two-
tailed Student’s t test was used to compare groups.  p values < 0.05 were considered significant.    
Results 
Virulence Studies 
We had shown previously that the VACV A35 gene is not required for replication and is 
a major virulence factor in the mouse i.n. challenge model, increasing virulence almost 100 fold 
(170).  It was unknown whether A35 would also play a role in infection via other challenge 
routes, or if perhaps A35 was required for replication in certain tissues such as nasal or lung 
tissue.  We therefore challenged groups of mice (n=5) intraperitoneally (i.p.), bypassing the 
respiratory route, with the wild type parental VACV WR strain, the A35Δ virus, or PBS as 
control.  We found that VACV (WR and A35Δ) injected i.p. did not cause any weight loss at 105 
and 106 pfu/mouse, but that at 107 pfu/mouse, the WR virus caused significant weight loss and 
death in 2 of 5 mice, while the A35Δ virus was attenuated, causing only mild weight loss and no 
mortality (Fig 21).  These data indicate that the A35 gene is required for virulence in mice 
infected by either the i.n. or i.p. route. 
Since A35 is a virulence factor independent of the route of infection, and VACV can 
block MHC class II antigen presentation in vitro (116, 163), we wanted to measure the effect of 
A35 on immune responses in vivo.  We anesthetized and i.n. infected groups of mice (n > 5) with 
the VACV WR strain, the A35Δ virus, or PBS as control.  Since we wanted to evaluate the 
immune responses in the presence or absence of the A35 gene without any confounding effects 
of overall systemic illness in the animals, we titrated the infectious dose to identify a dose of 
virus such that the more virulent WR strain did not cause significant weight loss in animals (Fig 
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22).  We found that 105 to 104 pfu/mouse caused significant weight loss and mortality in >80% 
of WR infected mice (approximate LD50 of 5 x 103 pfu (161)) by day 8, while all A35Δ infected 
mice survived (LD50 of 5 x 105 pfu).  At 103 pfu/mouse, WR caused significant weight loss while 
A35Δ did not, and 11/12 WR infected mice and all A35Δ infected mice survived. At 500 
pfu/mouse, no weight loss was noted at any time point for either virus (Fig 22); therefore, we 
chose 500 pfu/mouse as our infection dose to study immune responses to these viruses.   
Spleen Enlargement 
Visual observation during necropsy suggested that spleens of infected/vaccinated mice 
were larger than spleens of uninfected mice, and that spleens of A35Δ- infected mice were larger 
than spleens of WR-infected mice.  These observations suggested that A35Δ virus might 
generate a superior immune response with robust lymphocyte proliferation.  B and T 
lymphocytes proliferate in response to antigen, and a spike of T cell proliferation has been 
reported in the spleens and lymph nodes of mice days 5 to 7 after VACV infection was 
previously reported (223).  To begin to understand the effects of A35 on the immune response, 
mice were infected i.n. with 500 pfu of WR or the A35Δ virus. In all experiments, on at least one 
day (days 6-8 post infection), the spleens from A35Δ infected mice were significantly (p<0.05) 
larger than those from WR-infected mice (Fig 23a).  Enlarged spleens correlated with increased 
numbers of splenocytes isolated from spleens.  This difference was reproducible, but not 
significant.  A35Δ-infected mice had higher numbers of splenocytes than WR-infected mice; 
however the difference was lost by 9 dpi (Fig 23b).    
Antibody Response 
The effects of A35 on VACV specific immunoglobulin (Ig) production in mice were 
assessed.  The generation of anti-VACV specific antibody was previously shown to be crucial in 
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protecting mice from poxvirus infections (14, 32, 151). VACV-specific Ig was not detected 
above background levels on days 5 and 6 pi (i.n.).  By day 7, there was measurable anti-VACV 
Ig in the serum, and mice vaccinated with the A35Δ virus produced significantly more VACV-
specific Ig than mice infected with WR (Fig 24a), and this difference was maintained to 34 dpi 
(Fig 24b), the latest time point tested.  These data reveal that A35 inhibits the production of Ig 
during a specific immune response, and that even a highly attenuated virus can induce an equal, 
or even superior, antibody response compared to the wild type vaccine strain.  The B5R antigen 
is the major target of virus-neutralizing Ig in anti-VACV serum (12); therefore, we also 
measured Ig recognizing B5R protein in the sera of VACV-infected mice.  A35Δ infected mice 
also produced higher titers of B5R specific Ig, but the difference was not significant (Fig 24c).  
 Since A35Δ-infected mice produced higher VACV-specific antibody titers, we next 
compared the levels of neutralizing antibody present in the sera from WR and A35Δ-infected 
mice on day 34 pi.  Sera from WR-infected mice reduced plaque formation by an average of two-
fold compared to sera from mock-infected mice (data not shown).  Impressively, sera from the 
A35Δ-infected mice were able to reduce plaque formation nearly six-fold compared to sera from 
mock-infected mice and three-fold compared to the sera from WR-infected mice.  Together, 
these data indicate that infection with A35Δ not only generated larger amounts of total VACV-
specific Ig, it also lead to the production of larger amounts of neutralizing Ig.     
IFNγ-Secreting Splenocytes 
The ELISPOT assay allows enumeration of cells secreting IFNγ a cytokine known to be 
protective against VACV, in response to stimulation by VACV antigen presented in the context 
of MHC (42, 70, 180).  We tested how the presence of the A35 gene in the virus infecting mice 
i.n. affects the induction of IFNγ secreting cells in the spleens using two methods for antigenic 
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stimulation of IFNγ: the addition of VACV infected P815 cells (70) or the addition of infectious 
virus directly to the splenocytes (42).  As shown in Fig 25, splenocytes were stimulated to 
produce IFNγ by the addition of infectious virus directly to the cells, and the presence of the A35 
gene in the WR virus significantly reduced the number of VACV-specific IFNγ-secreting 
splenocytes developed by the mouse, in some cases by 10 fold.  Similar results were obtained 
when virus-infected P815 cells were used to stimulate the splenocytes (data not shown).  A35 
dependent differences were seen at early times pi (days 5 to 8), were significant on days 7 to 8, 
and were not consistently significantly higher at later times as the immune response waned (no 
significant differences were seen at day 9, 14 or 34). No IFNγ production was detected in PBS 
mock-infected mice or in any group without addition of virus or infected P815 cells as 
stimulators. 
CTL Activity 
Since cytotoxic T lymphocytes (CTL) are important in killing virally infected target cells 
and have been shown to be important in the defense against poxviruses (32, 88, 224), we 
measured the effect of A35 on CTL generated in spleens of i.n. infected mice. Splenocytes from 
PBS-, WR-, or A35Δ−infected mice were incubated with VACV-infected P815 target cells at 
various ratios, and specific lysis of the P815 cells was measured through the release of LDH into 
the supernatants.  As shown in Fig 26, A35Δ-infected mice developed significantly stronger 
VACV-specific cytolytic activity than WR-infected mice.  Differences were significant only on 
days 6 and 7 pi.  Together the immune data suggest that an A35Δ virus induces a significantly 
stronger B and T cell immune response especially early after infection/vaccination compared to 
wild type virus. 
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Cytokine Production 
In order to determine whether a cytokine signature could be identified for effective 
immune responses against poxvirus infection, and which cytokines might be mediating immune 
response differences in WR- and A35Δ-infected mice early after infection, we infected mice and 
harvested sera day 2 and 3 pi and measured 23 cytokines.  As shown in Fig 27, VACV infection 
altered the serum cytokine composition on day 2 pi compared to PBS mock-infected mice, 
increasing levels of IL-6, G-CSF, and MIP-1α significantly.  However, there was no significant 
difference between WR- and A35Δ-infected mouse sera that might explain the later differences 
in immune responses to these virus infections.  Sera levels of IL-2, IL-3, IL-4, IL-5, IL -10, IL -
12 p70, and eotaxin were below the standard curve values and are not shown. Day 3 data (not 
shown) were similar to day 2 with smaller differences between groups.   Thus, it was not 
possible to predict the effectiveness of an immune response based on early post infection serum 
cytokine levels.  We also assessed cytokine levels day 6 and 7 pi.  On day 6 pi, differences were 
small; however, on day 7 pi, serum levels of MCP-1, IFNγ, and G-CSF were elevated at least 
two-fold in WR- compared to A35Δ-infected mice, however as discussed below, viral titers were 
much higher in WR-infected mice at this time point, suggesting that these cytokines might be 
elevated in response to viral infection rather than immune response per se. 
Viral Titers in Organs 
We had shown previously that the A35 gene was not required for replication in numerous 
tissue culture cell lines (170), but it was possible that A35 increased virulence by allowing 
VACV to replicate in certain animal tissues.  We therefore wanted to compare virus replication 
levels in tissues both at early and late times after infection i.n. with WR and A35Δ viruses.  
Furthermore, since A35 inhibits the generation of an anti-VACV immune response in terms of 
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VACV-specific antibody production, IFNγ secretion, and CTL activity, we assessed viral titers in 
the organs at time points after development of the specific immune response (later than day 6) to 
assess whether the immune response was more effective in controlling virus in A35Δ infected 
mice. On days 1, 2 and 3 pi, there were no reproducible significant differences in WR and A35Δ 
virus titers in the tissues infected early after infection: lung, brain, nose, blood and spleen (data 
not shown).  However, on days 6-9 pi, WR infected mice usually had approximately 2-to 10-fold 
higher viral titers in most organs (sometimes more than 100-fold) than A35Δ (Fig 28), 
suggesting that the improved immune response in A35Δ infected animals was better controlling 
viral replication.  Peak titers were reached on day 7 for most organs, and after day 9 in these 
sublethally infected animals, titers dropped precipitously in the organs from both WR- and 
A35Δ-infected mice.   
Protection from Lethal Challenge 
We wanted to determine whether the A35Δ virus would act as a protective vaccine.  
Since immune recognition of A35 epitopes has not been found in the analysis of human or mouse 
B (antibody) or T cells (88, 153), we hypothesized that its deletion would not harm vaccine 
efficacy. Further, the improved immune responses (Figs 23-26) suggest that, in addition to being 
safer (Figs 21-22), the A35Δ virus might be a more efficacious vaccine. Mice were 
infected/vaccinated i.n. with a low dose of WR or A35Δ virus (103 pfu/mouse) or mock-
vaccinated with PBS.  Four weeks later, the mice were challenged with a high dose (LD50 x 450) 
of virulent WR virus.  Mock-vaccinated mice rapidly lost weight, and all died by 4 days post 
challenge (Fig 29a).  However all WR- or A35Δ-vaccinated mice survived to 3 weeks with only 
slight weight loss immediately after challenge.  The A35Δ virus mutant virus delivered i.p. also 
protected mice from virulent WR challenge (LD50 x 600) as well as the WR virus vaccination 
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(Fig 29b).   We tested vaccination over a range from 104 to 107 i.p., and   103 to 105 i.n., with 
challenge up to (LD50 x 1000), and found that in every case the A35Δ-vaccinated mice were fully 
protected from weight loss and death, and protected as well as the surviving WR-vaccinated 
mice.  We therefore predict that A35Δ mutant viruses will be superior vaccines. 
Discussion 
We have previously shown that the A35 gene is required for full virulence in the mouse 
respiratory infection model and that the protein is not required for viral replication (170).  Here 
we demonstrate that the A35 protein is also important for virulence when introduced i.p.  In the 
i.n. mouse model, our data here, together with our previous data (170), show that 106 pfu of 
A35Δ-mutant virus is required to reach the same level of weight loss caused by 103 pfu of WR 
virus, a 1000-fold difference. It is difficult to compare the virulence of various gene deletion 
mutants because many have not been tested in the i.n. model measuring weight loss; intracranial 
inoculations or measures of viral titers in organs have often been performed instead.  Available 
data indicate that the A35Δ virus is similar in virulence to the IL-18 binding protein knock out 
virus (159), more attenuated than the A46R deletion mutant (195), and less attenuated than the 
E3L deletion, which causes a 1000-fold attenuation (216).  
The A35 gene affects development of the host adaptive immune response.  Compared to 
WR-infected mice, mice infected with the A35Δ virus had larger spleens, generated higher titers 
of VACV-specific Ig and neutralizing antibody, and developed higher numbers of VACV-
specific IFNγ-secreting cells and improved CTL responses.  The faster and greater magnitude 
immune response that developed in the A35Δ-infected/vaccinated mice correlated with reduced 
viral replication in tissues.  It is important that viral titers 1 to 4 dpi (before development of a 
specific immune response) were not significantly different. Thus the control of virus replication 
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correlates with the enhanced immunogenicity of the A35Δ virus, suggesting that the immune 
response is responsible for decreases in virus titers. The relatively uniform reduction in viral load 
in multiple organs further implicates the immune control of virus rather than a tissue specific 
replication defect of the A35Δ mutant.   
Interestingly, the improved immune response seen in the A35Δ-infected/vaccinated mice 
was most evident on early days (days 6 to 8) pi, suggesting that A35 delays the generation of 
virus-specific immunity allowing the virus an advantage in establishing a generalized infection. 
We have shown (Fig 22) that differences in weight loss between WR- and A35Δ virus-infected 
mice occur at the time when the specific adaptive immune response is developing in A35Δ-
infected mice and delayed in WR-infected mice. This A35 mediated delay may allow enough 
time for the virus to replicate throughout the host organs and establish an infection in the mouse, 
resulting in weight loss and death.  In contrast, the superior immune response in the A35Δ-
infected mice results in a reduction in viral replication, clearance of the infection, and survival.   
While A35 seemed to delay T cell responses early, and the differences waned later during 
infection, the antibody response remained elevated in the A35Δ-infected mice to day 34 pi (the 
latest time point tested), indicating that the immune response is not only delayed by A35 in WR, 
but also persistently diminished even a month after infection.  Impressively, this enhanced 
antibody response in A35Δ-infected mice occurs despite the increased antigen load and 
persistence of antigen in WR infected mice (demonstrated by viral titer data for days 6 to 8 pi). 
Sublethal viral infection in a host may be simplistically considered in several overlapping 
steps; i) viral replication in tissues initially infected, ii) viral stimulation of and interaction with 
the innate immune system, iii) development of the specific immune response, iv) viral replication 
in target organs, and v) control of virus by immune mechanisms.  Our data suggest that A35 
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interferes with the development of the specific immune response, because early viral replication 
up to day 4 is not diminished in the A35Δ, and the difference seen between A35Δ and WR occur 
with the same kinetics as the development of specific immunity.  Since both B and T lymphocyte 
immunities are impeded by A35, it seems likely that A35 acts at an early stage in the initiation of 
a specific immune response, or potentially at the interface between innate and specific immunity.  
VACV is known to block MHC class II antigen presentation to CD4+ T lymphocytes (116).  
This would be predicted to result in smaller spleen size, which is indicative of decreased 
lymphoctye proliferation in this organ, and may also be expected to decrease Ig and CD8+ T 
lymphocyte responses that are dependent on CD4+ T helper cells.  CD4+, CD8+ and B 
lymphocytes are known to be important for protection from poxvirus infections (14, 32, 68, 151, 
224).  
The fact that the A35Δ mutant virus is highly attenuated and more immunogenic suggests 
that deletion of A35 will create superior vaccine strains. Indeed, in a lethal i.n. challenge model, 
the A35Δ virus vaccine, even at low doses, was as efficacious as WR in multiple challenge 
experiments up to 1000 x LD50.  It is important not to delete viral genes that contain protective 
epitopes from vaccine strains.  Several groups have identified the CD4+ (26) and CD8+ (55, 88, 
97, 148, 208) T cell epitopes that confer protection to poxviruses.  None of these studies has 
identified A35 as a T cell determinant.  Other groups have analyzed human vaccinia immune 
globulin in an effort to determine the VACV antigens that it recognizes (48, 91).  Again, A35 
was not among the reactive VACV antigens.  Thus removal of the A35 gene is anticipated to 
improve vaccine safety, while having no detrimental effect on the generation of a protective 
immune response in mammals.  Indeed the immune response is enhanced in A35Δ-infected 
animals.  This is important for the development of poxvirus vaccines, especially for post-
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exposure vaccination, which requires a rapid immune response for protection.  In addition, 
poxvirus platform vaccines for other infectious diseases and cancer will likely benefit from 
removal of the A35 gene.   
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Figures 
Figure 21: Intraperitoneal infection of mice.  Groups (n=5) of female BALB/c mice were 
infected i.p. with 107 pfu/mouse of WR or A35Δ virus, or mock-vaccinated with PBS, and 
weighed (g +SEM) at various time points pi.  * Two mice died in the WR infected group.   
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Figure 22: Intranasal infection of mice.  Groups of mice were infected i.n. with 500 to 105 
pfu/mouse of WR or A35Δ virus, or mock-vaccinated with PBS and weighed (g +SEM) for 4 
weeks. Weights increased after day 9.  *All mice (5/5) died in the group infected with 105 pfu 
WR, 6/7 mice died in the group infected with 104 pfu WR, and 1/11 mice died in the group 
infected with 103 pfu WR.   No A35Δ-infected mice died.   
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Figure 23: Spleen weights and counts. Mice were infected with WR or A35Δ virus i.n. on day 
0 with 500 pfu/mouse.  Five mice per infection group were sacrificed, their spleens were 
weighed on day 7 (a), and total splenocytes were counted (b).  Data show the average (+/- SEM).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121  
 
 
 
 
 
 122  
Figure 24: VACV- and B5R-specific antibody response.  Mice (n=5) were infected i.n. with 
WR or A35Δ virus, and blood was collected on various days pi.  Serum reactivity was measured 
by ELISA on VACV-coated plates for day 7 (a) or day 34 (b) sera, or on purified B5R-coated 
plates (c) for day 7 pi sera.  Data show the average absorbances (+/- SEM). OD405, optical 
density at 405 nm.   
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Figure 25: VACV-specific IFNγ-producing cells.  On days 6, 7 and 8 pi (i.n.), the spleens from 
five mice/group were harvested and splenocytes were analyzed by ELISPOT for virus-specific 
IFNγ production 48 h after stimulation with VACV-WR virus.  Data show the average number of 
spots (+/- SEM). 
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Figure 26: Cytotoxic T lymphocytes.  Mice were infected i.n. on day 0 with 500 pfu/mouse of 
WR or A35Δ virus.  On day 7 pi, the spleens from five mice/group were harvested and the 
splenocytes were incubated with WR-infected (MOI=5 for 3 h) P815 cells as targets.  After 6 h, 
supernatants were collected and analyzed for the presence of LDH.  Data show the average lysis 
(+/- SD).  OD492, optical density at 492 nm.     
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Figure 27: Cytokines in blood.  Mice were infected i.n. on day 0 with 500 pfu/mouse of WR or 
A35Δ virus or PBS, and sera were collected on day 2 pi and analyzed for cytokine quantities (+/- 
SEM) by using a Luminex Bioplex assay. TNFα values were divided by 20 to better show all 
data. 
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Figure 28: Viral titers in organs.  Mice were infected i.n. with 500 pfu/mouse of WR or A35Δ 
virus, and organs were harvested from five mice per group per day into 1 ml cold RPMI medium.  
To quantify viral replication, organs were freeze/thawed three times, homogenized, and 
sonicated before titration on BS-C-1 cells.  Monolayers were stained ~40 h later with crystal 
violet and the plaques were counted.  Data show the average (+/- SEM).  Lung and nose titers 
were divided by 2, and heart, liver, kidney were multiplied by 20, 50, and 100 respectively in 
order to make data more visible.  
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Figure 29: Protection from lethal challenge.  (a) Mice were vaccinated i.n. on day 0 with 1000 
pfu of WR or A35Δ virus, or mock-vaccinated with PBS.  Four weeks later, the mice were 
challenged i.n. with LD50 x 450 virulent WR virus.  (b) Mice were vaccinated i.p. with 106 or 107 
pfu and challenged 4 weeks post vaccination with LD50 x 600 WR. 
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CHAPTER 5: DELETION OF THE A35 GENE FROM MODIFIED VACCINIA 
ANKARA INCREASES IMMUNOGENICITY, ISOTYPE SWITCHING, AND CREATES 
AN EFFECTIVE POXVIRUS VACCINE 
Abstract 
The Vaccinia virus (VACV) A35 gene (Copenhagen designation) is highly conserved in 
mammalian tropic poxviruses and is an important virulence factor in the mouse model, but it is 
not required for replication in the VACV Western Reserve strain. Futhermore, the protein 
mediates suppression of in vitro MHC class II-mediated antigen presentation and suppresses 
immune responses in mice.  The Modified Vaccinia Ankara (MVA) virus has been used as a 
safer alternative poxvirus vaccine; however, concerns about its immunogencity and efficacy have 
been raised.  Herein, we show that A35 is not required for the normal viral spread and replication 
of MVA in BHK-21 cells, and that infection of mice with an MVA A35 deletion mutant 
(MVA35Δ) virus enhanced B and T lymphocyte responses compared to MVA.  Specifically, 
mice infected with the MVA35Δ virus had enhanced class switching to IgG isotypes and 
increased numbers of virus-specific IFNγ- secreting splenocytes.  Both MVA and the MVA35Δ 
virus were able to protect mice equally from a lethal challenge (500 x LD50).  Our data suggest 
that the deletion of the A35 gene may be an effective strategy to enhance the immunogenicity of 
MVA-based vaccines without decreasing efficacy.     
Introduction 
Vaccinia virus (VACV) was used as the live virus vaccine during the smallpox 
eradication campaign, and its use ultimately led to the eradication of this fatal disease (124).  
Despite being phenomenally successful, vaccination of the general public was discontinued due 
to the unacceptably high rate of adverse events, including disseminated vaccinia, progressive 
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vaccinia, eczema vaccinatum, and encephalitis (111).  It has been estimated that 25% of the 
current population should not be vaccinated due to immunosuppression, inflammatory skin 
conditions, pregnancy, or heart abnormalities (60, 96, 211), and 1 out of every 450 people 
vaccinated will have a serious adverse reaction resulting in hospitalization (29).   
 Since the discontinuation of widespread poxvirus vaccination, there has been an increase 
in the incidence of human poxvirus infections throughout the world, including buffalopox in 
India (100), Cantagalo virus in South America (45, 185) and cowpox in Europe (107).  The most 
dangerous emerging poxvirus is monkeypox, which is a zoonotic poxvirus that causes a 
smallpox-like illness and has a 10% fatality rate in humans.  Monkeypox is endemic to Africa, 
but in 2003 there was an outbreak in the United States that was associated with the importation 
of African rodents (34, 112).  This outbreak resulted in approximately 80 cases, but because this 
was an attenuated strain, no deaths occurred (34, 115).  In addition to the threat of emerging 
poxvirus infections, there is also concern that the smallpox virus could be used as a biowarfare 
agent, resulting in widespread sickness and mortality in a now largely unvaccinated population.  
Thus, safer poxvirus vaccines are needed in the face of emerging disease and bioterrorism. 
 A safer alternative to the traditional poxvirus vaccine is the use of attenuated, replication-
deficient strains, such as Modified Vaccinia Ankara (MVA).  Attenuation of this virus occurred 
after >570 serial passages in chicken embryo fibroblasts (CEF), resulting in deletion of 
approximately 25 kb of the VACV genome (136), including genes encoding immunomodulatory 
proteins (17), and the inability to replicate in most mammalian cells (17).  MVA is being tested 
as a vaccine to protect against poxviruses (57, 67, 202), and is also being used as a platform 
vaccine for other infectious diseases and cancer (59, 105, 166). Poxviruses make good platform 
vaccines because they are easy to produce and stable, induce robust, long lasting cellular and 
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humoral immune responses, and can accommodate the insertion of large pieces of foreign DNA 
(169).  MVA has been shown to be safe when administered to immunodeficient mice (221), non-
human primates (201) and humans (125, 199).  Recent vaccine trials have shown that MVA can 
be given safely to those infected with HIV (41) and those with atopic dermatitis (90), two 
populations that cannot receive the traditional vaccine.  Thus, this attenuated VACV shows 
promise as a safer alternative poxvirus vaccine and also as a platform vaccine. 
 While MVA is clearly safer, there are concerns about its immunogenicity and efficacy 
(8).  In studies comparing the immunogenicity of MVA to traditional poxvirus vaccines, MVA 
was unable to elicit the same levels of both antibody and IFNγ-producing cells as traditional 
poxvirus vaccine strains, even when 10-100 times more virus was administered, although both 
viruses offered similar levels of protection (14, 67, 221).  The immunogenicity of MVA may 
especially be a concern in populations with an already weakened immune system, such as cancer 
patients.  Data available suggest that multiple doses of MVA may need to be administered in 
order to achieve the level of immunogenicity obtained with traditional replication-competent 
strains (14).  One strategy that can be used to enhance the immunogenicity of MVA is to identify 
and exclude genes that are immunosuppressive.  The Copenhagen A35 gene (Western Reserve 
strain gene 158, MVA gene 146R) is one such gene. 
 We have previously shown that the poxvirus A35 gene is highly conserved in all 
sequenced mammalian-tropic poxviruses, including MVA (170).  It is an important virulence 
factor in the mouse model, increasing virulence by nearly 1000-fold, but is not required for 
replication of the VACV Western Reserve (WR) strain (164, 170).  In addition, we have shown 
that A35 suppresses in vitro MHC class II-restricted antigen presentation (162), and, following 
intranasal (i.n.) infection in mice, the protein mediates immunosuppression, significantly 
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decreasing virus-specific antibody production, IFNγ-secreting T cells, and CTL killing, resulting 
in the inability to control viral replication in target organs and thus contributing to morbidity and 
mortality of the host (164).  Here, we characterize the A35 gene function in the background of 
the MVA genome.  
Materials and Methods 
Cells and Virus 
VACV Western Reserve (WR) stocks were propagated using BS-C-1 cells in MEM 
containing 10% FBS as previously described (170).  MVA and MVA35Δ stocks were propagated 
using BHK-21.  P815 and BHK-21 cells (ATCC) were grown in DMEM containing 10% FBS. 
Immunostaining of Virus Infected Cells 
Immunostaining was performed as previously described (171).  Briefly, BHK-21 cells 
were infected with a titration of either the MVA or MVA35Δ virus for 72 h.  Cells were then 
incubated with a 1:1000 dilution of polyclonal VACV rabbit antiserum (BEI Resources NR629) 
for 1 h at 4o C, followed by incubation with a 1:1000 dilution of goat anti-rabbit IgG-horseradish 
peroxidase (HRP) for 1 h at 4o C.  1 ml of the following substrate solution was then added to the 
wells to visualize virus-infected cells: 12 µl of 30% H2O2 and 240 µl of dianisidine-saturated 
ethanol in 12 ml of PBS.        
Construction of the MVA35Δ  Mutant Virus 
The DNA segment containing the A35 flanking regions and the E. coli xanthine guanine 
phosphoribosyl transferase (gpt) gene was amplified from the existing vA35Δ mutant made from 
WR (170) using the primer pair TCGTGTTCATGATCTTGTTC and 
TTGCCTAGACCGGATACTA.  The PCR product was then transfected with N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP; Roche) into BHK-21 
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cells infected with the MVA strain.  The mutant viruses were selected in media containing 
mycophenolic acid (Sigma).  Recombinant viruses (two independent mutant lines) were plaque 
purified three times by using the immunostaining protocol described above and crude stocks 
were propagated in BHK-21 cells containing 10% FBS using previously described methods 
(170).  Crude virus lysates were prepped for PCR by incubation with an equal volume of 2x PCR 
buffer (0.9% IGEPAL, 0.9% Tween-20, 20 mM Tris-HCl, pH 8.3, 3 mM MgCl2, 100 mM KCl) 
and 0.3 mg/mL Proteinase K for 30 m at 45o C, followed by heat-inactivation of the Proteinase K 
for 10 m at 94o C.   The recombinant viruses were then PCR screened for the absence of A35 
gene using the primers described above.  All immunologic experiments were performed using 
both independently derived MVA35Δ mutant virus isolates to confirm that any difference seen 
compared to MVA was due to the deletion of the A35 gene.  
Western Blotting 
 Western blots were performed as previously described using polyclonal rabbit anti-A35 
sera (170).    
One-Step Growth Curve 
A one-step growth curve was performed to measure viral replication as previously 
described (170).  Virus foci were enumerated using the immunostaining protocol already 
described above.  
Mouse Vaccinations 
Female BALB/c mice (n=5) were infected intramuscularly (i.m.) with 107 pfu MVA or 
one of the two MVA35Δ viruses in 100 µl, or mock infected with PBS.  Titers were confirmed 
on the day of infection with the virus dilution used to infect the animals. For challenge 
experiments, mice were vaccinated i.m. as described above and then infected intranasally (i.n.) 4 
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weeks later with 500 x LD50 of virulent WR (164).  Mice were weighed and monitored daily for 
signs of illness, and were humanely euthanized using isoflurane overdose if 20% weight loss 
occurred. For experiments assessing the immune response, five mice from each virus group were 
sacrificed and the spleens were collected in ice cold RPMI.  Splenocytes were obtained using 
previously described methods (36, 164).  Blood was collected using a cardiac stick, followed by 
centrifugation to separate out the antibody-containing serum from the RBCs.   All experimental 
protocols were approved by the Animal Care and Use Committee of East Carolina University. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Antibody response was measured similar to our previous work (164). Ninety six-well 
ELISA plates (Immulon H2B Thermo Electron) were coated overnight with 0.1 µl/well (100 µl) 
crude WR virus in ELISA coating buffer (10.3 g H2BO4, 7.31 g NaCl, 1 l ddH2O, pH 8.5) at 4°C. 
Plates were blocked with 1% FBS/PBS at room temperature for 30 min. Plates were washed with 
ELISA wash buffer (1x PBS, 0.02% Tween 20, 0.1% NaN3) and a titration of mouse sera from 
MVA or MVA35Δ-vaccinated mice (n=5) was added. Plates were incubated at room temperature 
for 2 h and washed. Alkaline phosphatase (AP)-conjugated goat anti-mouse Ig, IgM, IgG, IgG1, 
or IgG2a (Southern Biotech) was added and incubated at room temperature for 1 h. Plates were 
washed 3 times, developed (BioRad Alkaline Phosphate Substrate Kit) and absorbance was read 
at 405 nm.   
IFNγ  Elispot 
Numbers of IFNγ secreting spleen cells were enumerated similar to our previous work 
(164). Ninety six-well plates (Immulon H2B Thermo Electron) were coated overnight with 0.2 µl 
anti-mouse IFNγ (1 mg/ml Pharmingen) at 4°C.  Plates were washed with blocking buffer before 
adding a titration of murine splenocytes in RPMI 1640. Stimulation of splenocytes was achieved 
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by either the addition of WR virus only (multiplicity of infection (MOI)=2) or with the use of 
50,000 WR-infected (MOI=3) P815 stimulator cells, followed by incubation for 40 h at 37°C.  
Plates were then washed and incubated with 0.4 µl biotinylated rat anti-mouse IFNγ (Pharmingen 
0.5 mg/ml) for 2 h at 37°C.  Plates were washed again and incubated with streptavidin-AP for 1 
h at 37°C.  Plates were developed with agarose/BCIP/AMP mixture, and spots were counted 
using a dissecting microscope or color intensity was read at an absorbance of 492 nm.   
Flow Cytometry 
Cell types present in spleens were analyzed by flow cytometry.  Splenocytes (106) from 
MVA or MVA35Δ-vaccinated mice (n=5) were fixed in 3% paraformaldehyde on ice for 5 min, 
washed, and then incubated for 15 min with an anti-Fc block (BD Pharmingen) to block non-
specific binding of antibodies to Fc receptors.  The following anti-mouse allophycocyanin 
(APC)-, Pacific Blue (PacBl)-, phycoerythrin (PE)-, or phycoerythrin-cyanine 7 (PE-Cy7)-
conjugated monoclonal antibodies were then added to the samples for 45 min on ice: CD8a/Lyt-2 
(clone 53-6.7, Southern Biotech); CD11b (clone M1/70, eBioscience); CD11c (clone N418, 
eBioscience); CD45R/B220 (clone 30-F11; eBioscience); CD49b (Dx5, NK marker; BD 
Pharmingen); Ly-6G/Ly-6C (granulocyte marker, clone RB6-8C5; BD Pharmingen); F480 
(macrophage marker; Caltag Labs); MHC II (I-A/I-E, clone M5/114.15.2; eBioscience).  
Samples were run on an LSR II flow cytometer and data were analyzed using the FACS Diva 
software.   
Statistical Analyses 
Experiments were repeated at least 2 times and representative data are shown.  A two-
tailed Student’s t test was used to compare groups.  p values < 0.05 were considered significant.    
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Results 
Molecular Characterization of MVA35Δ  
We previously have shown that A35 in VACV strain Western Reserve (WR) inhibits in 
vitro MHC II-restricted antigen presentation (162) and suppresses both the T and B lymphocyte 
response in mice infected i.n. (164).  We next wished to determine if removal of A35 from an 
attenuated vaccine strain would affect replication or increase immunogenicity using the 
attenuated poxvirus strain MVA.  To determine the role of A35 during infection with MVA, a 
mutant virus missing the A35 gene was constructed.  Similar to our previous A35 deletion 
mutant in the WR strain (designated A35Δ) (170), a PCR product containing the E. coli gpt gene 
with A35 flanking regions on either side was transfected into MVA-infected cells, and 
recombinant viruses were selected and purified.  To confirm that A35 had been successfully 
knocked out of MVA, PCR analysis was performed using primers in the flanking regions.   As 
shown in Fig 30a, PCR amplification of the parent MVA virus yielded a product of 1.5 kb, and 
PCR analysis of two independently isolated MVA35Δ mutants resulted in an approximately 400 
base pair larger product when compared to the product from MVA.  This is the expected size 
increase as a result of the insertion of gpt-containing PCR fragment.  There was no wild type 
A35 detected in the mutants suggesting that the A35 gene had been successfully removed and 
indicating that the mutants were purified from MVA parental virus.  To further confirm the 
absence of A35 from the recombinant viruses, a Western blot was performed to analyze 
reactivity with rabbit anti-A35 polyclonal sera (170) using lysates from MVA and MVA35Δ 
infected cells (Fig 30b).  A protein band of about 23 kD (the approximate size of A35 (170)) was 
recognized in the lysates from the WR and MVA-infected cells, and this protein band was absent 
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in the A35Δ and MVA35Δ-infected cells.  Together, these data indicated that A35 was 
successfully knocked out of MVA in these two independently derived mutants. 
MVA35Δ  Virus Replicates Normally 
We previously reported that an A35Δ mutant virus made from WR formed normal size 
plaques on the African green monkey kidney cells BS-C-1 and replicated normally in several cell 
lines and mouse tissues (162, 164, 170), but it was possible that the loss of A35 in WR was being 
compensated for by another VACV protein.  Since MVA is missing ~ 25 kb of the genome of 
VACV, we assessed whether A35 might be required for MVA replication.  The MVA35Δ virus 
formed normal, MVA-sized foci on BHK-21 cells (Fig 31a), indicating that the loss of A35 had 
no apparent effect on normal viral replication and spread in these cells.  To compare the kinetics 
of replication of the MVA35Δ virus with the parental MVA virus, we performed a one-step 
growth curve (Fig 31b).  BHK-21 cells were infected (MOI=10) with either MVA35Δ or MVA 
for 2 h, and then inocula were removed.  At various times post infection, cells and media were 
collected and the amount of virus in each was determined by titration on BHK-21 cells.  For 
virus produced in the cells, there was <2-fold difference between the amount of virus produced 
by MVA and MVA35Δ at all time points tested.  Similarly, for virus in the supernatants, 
MVA35Δ showed no decrease in virus production.  Together, these data indicate that A35 is not 
required for the normal replication and release of MVA in BHK-21 cells and further our 
conclusion that A35 is not required for VACV replication or spread from cell to cell.     
Infection of Mice with MVA and MVA35Δ  
The loss of A35 in virulent WR results in a 1000-fold decrease in virulence in the mouse 
model (164). To determine whether the deletion of A35 had any effect on the avirulence of 
MVA, mice were infected intramuscularly (i.m.) with 107 pfu MVA or one of the two MVA35Δ 
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mutant viruses, a typical route of administration of MVA at a dose that has been shown to elicit a 
measurable immune response (14, 67, 221), or mock-infected with PBS as a control.  Mice were 
weighed and monitored daily for lesions or signs of illness.  As shown in Fig 32, mice infected 
with either MVA or MVA35Δ gained weight similar to PBS control and had no signs of illness.  
Similar results were seen with infection no matter which MVA35Δ virus was used.  In contrast, 
intranasal (i.n.) vaccination of mice with 103 pfu virulent WR results in significant weight loss 
and death (164, 170).  These data confirm that the avirulence of MVA is not altered by the loss 
of A35 from the genome.     
Antibody Response to Infection with MVA35Δ  
An effective poxvirus vaccine should elicit both a humoral and a cellular immune 
response, as both arms of the immune system have been shown to mediate aspects of protection 
against poxvirus infections (14, 32, 224).  Our previous data with WR indicated that removal of 
A35 results in an increase in both cellular and humoral immunity (164), so we hypothesized that 
the removal of A35 from MVA would boost its immunogenicity, but this was not known.  In WR 
is was possible that A35 interacted with another viral protein to be functional, and since MVA is 
has several large deletions, this interacting protein may have been deleted, rendering A35 non-
functional.  To begin to understand the effects of A35 in MVA on the immune response, we 
compared the production of anti-VACV specific Ig in the sera of mice infected with either MVA 
or MVA35Δ (Fig 33).  Mice infected with MVA35Δ had significantly greater amounts of total 
VACV-specific serum Ig than those infected with MVA on days 7 and 10 pi.  We also analyzed 
the production of various antibody isotypes on days 7 and 10 pi (Fig 34), and, by day 10, mice 
infected with MVA35Δ virus produced significantly more VACV-specific IgG, IgG1, and IgG2a 
than those infected with MVA.  There was no significant difference in IgM production on these 
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days.  Infection with either mutant MVA35Δ virus yielded similar results and representative data 
are shown.  These data suggest that A35 in MVA decreases VACV-specific antibody production 
and inhibits isotype switching. 
T Lymphocyte Response to Infection with MVA35Δ  
In order to measure the effect of A35 in MVA on the cellular immune response to 
infection, we used the ELISPOT assay to measure IFNγ production as a result of stimulation 
with VACV antigens presented in MHC (42, 70, 180).  IFNg is an important anti-poxvirus 
cytokine.  Mice were infected and on day six pi their splenocytes were harvested and stimulated 
to produce IFNγ by adding virus directly to the splenocytes.  There was significantly more 
VACV-specific IFNγ production in the cells of mice infected with MVA35Δ compared to the 
mice infected with the parental MVA (Fig 35a).  On day 10 pi, there was a three-fold increase in 
the number of IFNγ producing spleen cells in the MVA35Δ group compared to the MVA group, 
but this difference did not reach statistical significance.  Similar results were seen with both 
MVA35Δ  mutant viruses and when splenocytes were stimulated with VACV-infected P815 
cells.  No IFNγ was produced by splenocytes from PBS control mice or in any of the groups 
without addition of virus or infected P815 cells, thus demonstrating the specificity of the 
response.  Since CD8+ T cells produce most of the IFNγ following a VACV infection (224), we 
also measured the percentage of CD8+ T cells in the splenocytes of infected mice on days 7 and 
10 pi (Fig 35b).  We found that MVA infection significantly increased the percentage of CD8+ T 
cells in the spleens, but there was no difference between the MVA and MVA35Δ-infected 
groups.   
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Measurement of Cellular Subsets in the Spleens 
We had previously noted that VACV WR infection induces splenomegaly, presumably as 
a systemic specific immune response develops, and that spleen size increased most when mice 
were infected with a virus that is missing the immunosuppressive A35 gene (164). To understand 
more about the mechanism of A35-mediated immunosuppression during infection with MVA, 
we performed a flow cytometry experiment to measure the percentage of cellular subsets within 
the spleens of MVA and MVA35Δ-infected mice.  On day 6 pi, there was little change in 
splenocyte populations (Fig 36).  There was a small but significant increase in the percentage of 
cells containing the macrophage marker CD11b+ and a marker for granulocytes in the 
splenocytes of the MVA35Δ-infected mice compared to MVA-infected mice (Fig 36a).  The 
CD11b+ difference was maintained on day 8 pi (data not shown).  Also, on day 8 pi, there was a 
small but significant increase in the percent of DX5+ natural killer (NK) cells found in the 
MVA35Δ group compared to the MVA group (data not shown).  Since our in vitro data indicate 
that A35 specifically affects the APC (162), we also looked at APC subsets within the spleen, 
including B cells (B220+CD11c-), macrophages (CD11b+CD11c-), and dendritic cells (CD11b-
CD11c+), and found that on day 6 pi, there was a small but significant increase in the percent of 
macrophages in the spleens of the MVA35Δ-infected mice compared to those infected with 
MVA (Fig 36b).  There was no significant difference between the groups in the percentage of 
total MHC class II expressing cells (Fig 36a).   Thus, infection with MVA results in a small but 
significant increase in cells expressing CD8 (Fig 35b), and A35 modestly reduces an infection-
induced increase in the percentage of granulocytes and CD11b+ expressing cells in spleens (Fig 
36). 
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MVA35Δ  Protects Mice from Lethal Challenge 
It was next determined whether the MVA35Δ virus would be an efficacious vaccine and 
protect mice from a lethal VACV challenge.  Removal of A35 from the WR strain of VACV did 
not reduce vaccine efficacy (164).  Many studies have been performed to determine the 
protective antigenic epitopes of VACV (88, 91), but only the most recent has identified A35 as 
containing possible CD8+ T cell epitopes (89).  We therefore tested whether the removal of A35 
from MVA would decrease vaccine efficacy due to the loss of predicted protective epitopes or 
perhaps increase efficacy due to enhanced immune responses.  Mice were vaccinated i.m. with 
107 MVA or MVA35Δ, or PBS as control, and four weeks later were challenged i.n. with 500 x 
LD50 virulent WR virus (Fig 37).  PBS control mice quickly lost weight and all died by 4 days 
post challenge.  All MVA or MVA35Δ vaccinated mice survived the challenge with no 
significant weight loss and no signs of illness.  Similar data were obtained no matter which 
MVA35Δ virus was used to infect the mice.  Together, these data support the hypothesis that an 
MVA-based vaccine that excludes the A35 gene will be both protective and highly 
immunogenic.   
Discussion 
We have previously shown that the VACV A35 protein in WR is a virulence factor in the 
mouse model, increasing virulence by nearly 1000 fold and decreasing immunogenicity (164, 
170).  In this manuscript, we provide a characterization of A35 in the highly attenuated VACV 
strain, MVA.  In WR, we have not demonstrated a role for A35 in replication (164, 170), but it 
was possible that its loss was being compensated for by another redundant VACV gene. Since 
MVA is missing nearly 25 kb of the VACV genome (136), including most immunomodulatory 
genes (17), we tested whether A35 was required for replication of MVA.  We could not uncover 
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a replication function for A35 in MVA using BHK-21 cells (Fig 31); however, A35 may have 
been retained by MVA because it is necessary for the replication of the virus in avian cells 
(CEF), the cells used during its attenuation.  During its > 570 passages in CEFs, MVA lost many 
of the immunosuppressive genes that are found in VACV, including the secreted receptor 
homologs for IFNγ, IFNα, IFNβ, and TNF (17).  It is interesting to note that MVA did retain a 
few immunoevasion genes, including the IL-1β receptor homolog (17) and A35 (170).  It is 
unknown as to why only certain immunosuppressive genes were kept by MVA since these genes 
would not have been necessary for the survival of the virus in CEF.  Perhaps these genes serve 
different functions for the virus in the avian host.  We are currently performing experiments to 
determine whether A35 may be needed for the replication of MVA in avian cells. 
Due to its avirulent phenotype, MVA is being tested as an alternative poxvirus vaccine 
and is also being used as a platform vaccine for delivering various other antigens, including those 
for cancer and HIV (59, 104, 166).  Unfortunately, MVA fails to elicit the same levels of B and 
T cell responses as the traditional replicating poxvirus vaccines (14, 67, 221).  This will 
especially be a concern when vaccinating persons with already weakened immune systems, such 
as those infected with HIV, cancer patients, and transplant recipients, as these individuals will 
require higher or multiple doses of the vaccine compared to those with a competent immune 
system.  It is therefore important to develop strategies to increase the immunogenicity of MVA.  
Our previous work with A35 in WR suggested that the removal of A35 from MVA would result 
in a more immunogenic vaccine (164).  It was therefore important to elucidate the functional 
effects of the A35 gene ortholog in this attenuated VACV strain.  In WR, it was possible that 
A35 interacted with another viral protein and that this interaction was required for A35 to be 
functional.  Since MVA is missing nearly 25 kb of the VACV genome (136), it was possible that 
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any protein that interacted with A35 may have been deleted, rendering A35 ineffective.  We 
show here that A35 does indeed function to suppress the specific immune response in the 
background of the MVA genome.    Specifically, i.m. infection of mice with MVA35Δ virus 
resulted in increased antibody production, isotype switching, and IFNγ secreting T cells.  This is 
consistent with our previous work with A35 in WR (164) and provides further evidence that that 
the removal of A35 from poxvirus-based vaccines will enhance their immunogenicity.  In WR, 
the improved immune response in the absence of A35 correlated with improved control of virus 
replication in target organs (164), but since MVA does not replicate in mammalian tissues, we 
could not perform those experiments here.  We also show that MVA35Δ virus can protect mice 
as well as MVA from a virulent challenge.  While many studies have been performed in an 
attempt to identify the protective antigenic B and T cell epitopes of VACV (48, 88), only the 
most recent of these has identified A35 as containing antigenic CD8+ T cell epitopes (89).  Our 
data presented here (and previous data with WR (164)) indicate that the removal of A35 has no 
measurable effect on vaccine efficacy in our challenge model, as the MVA35Δ virus protected 
mice as well as MVA from a virulent challenge (Fig 37).      
 A35 in MVA decreased the production of VACV-specific IFNγ-secreting cells (Fig 35a), 
but it did not affect the percentage of CD8+ T cells in the spleens of these mice (Fig 35b). NK 
and CD4+ and CD8+ T cells can secrete IFNγ, but studies have implicated the CD8+ T cells as 
the main IFNγ secreting cells during VACV infection (57, 221, 224).  Our results indicate that 
either A35 reduces the amount of virus specific IFNγ secretion without reducing the percent of 
CD8+ T cells in the spleen, suggesting that A35 either decreases the amount of IFNγ secretion on 
a per cell basis or blocks the production of this cytokine from another subset of IFNγ-producing 
cells, such as CD4+ T cells or NK cells.  Interestingly, we did see a small but significant 
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decrease in the percent of NK cells in the spleens in the MVA-infected mice compared to those 
infected with MVA35Δ on day 8 pi.  Splenocytes from infected mice will need to be stimulated 
with VACV and then double stained with antibodies to IFNγ and CD8, CD4, or DX5 in order to 
determine specifically which IFNγ-secreting cell type A35 is affecting. 
A35 also inhibited the generation of VACV-specific antibody (Fig 33-34).  We measured 
total Ig, IgM, IgG, IgG1, and IgG2a, and found that A35 had no effect on IgM production, but 
did significantly decrease Ig, IgG, IgG1, and IgG2a.  IgG2a and IgG1 can be used as a measure 
of the Th1 and Th2 immune responses, respectively, (183).  Compared to a Th2 response 
following VACV infection, a predominantly Th1 response is associated with smaller lesion size 
and decreased viral replication (150, 179).  Furthermore, following VACV infection, persons 
with atopic dermatitis produce higher levels of cytokines and antibodies associated with the less 
protective Th2 response (11), resulting in uncontrolled replication of virus in the skin.  We found 
no evidence that A35 was mediating immune deviation by skewing the immune response 
towards the less protective Th2 response since IgG1 production was not increased in the 
presence of A35.  We also measured the levels of VACV-specific IgM, the first antibody to be 
produced during an infection, and found that A35 had no effect on the production of this 
antibody on days 7 and 10 pi.  On these same days, there were significantly higher levels of the 
other antibody isotypes measured in the MVA35Δ-infected mice compared to the MVA-infected 
mice.  These data indicate that mice infected with the MVA35Δ virus had enhanced switching of 
antibody to the more protective isotypes, such as IgG and its various subclasses.   
Our data with A35 indicate that the protein regulates the host adaptive immune response.  
The presence of A35 in both WR and MVA correlated with decreased T and B lymphocyte 
responses in mice.  Our data using the WR virus model showed that the removal of the A35 gene 
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caused elevated antibody levels at least a month after vaccination (164), suggesting that A35 
deletion mutant viruses may give effective protection for longer time periods.  Since MHC class 
II antigen presentation to CD4+ T cells is necessary for the generation of optimal T and B cell 
immune responses in mice (224), it would be interesting to see if splenocytes from MVA- or 
WR-infected mice would be deficient in presenting antigen to CD4+ T cells ex vivo, as compared 
to MVA35Δ- and A35Δ-infected mice, similar to what we have observed following in vitro 
infection with VACV (162).  It has been reported that splenic DCs from VACV-infected mice 
were deficient in presenting a model antigen to specific CD4+ T cells, but no VACV gene was 
identified as contributing to this effect in this model (227), so this would indeed be an exciting 
find.  Nevertheless, the data presented further support that the removal of A35 from any 
poxvirus-based vaccine would result in increased antibody and T cell responses.    
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Figures 
Figure 30:  Molecular characterization of MVA35Δ .  a) PCR.  MVA-infected cells were 
transfected with a recombinant PCR fragment containing the E. coli gpt gene inserted between 
the A35 flanking regions and recombinant viruses were selected in mycophenolic acid-
containing media.  Virus crude stocks were PCR analyzed using primers in the A35 flanking 
regions.  Wild type A35 locus yields a product of 1400 kb size and the mutants with gpt inserted 
yield a size of approx 1900 kb.  b) Western blot showing that A35 is not expressed in MVA35Δ-
infected cells.  BHK-21 cells were infected with listed viruses at an MOI of 20 for 2 h and 
analyzed by SDS-PAGE.  Blots were incubated with rabbit anti-A35 antibody at a 1:1000 
dilution and developed with an anti-rabbit alkaline phosphatase-conjugated secondary antibody 
followed by incubation with the substrate Western Blue (Promega).   
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Figure 31: A35 is not required for replication of MVA.  a)  MVA and MVA35Δ mutant 
viruses form similarly sized foci on BHK-21 monolayers.  Virus-infected cells were visualized 
by immunostaining.  b)  One step growth curve. BHK-21 cells were infected (MOI=10) with 
MVA or MVA35Δ, and the amount of virus associated with cells and in the supernatants was 
titered on BHK-21 cells at various times post infection.   
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Figure 32: Infection of mice with MVA and MVA35Δ .  Groups of mice (n=5) were infected 
i.m. with 107 pfu/mouse of MVA or MVA35Δ virus, or mock-vaccinated with PBS and weighed 
(g +SD) for 4 weeks.  No mice lost weight or showed signs of illness.   
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Figure 33: VACV-specific antibody response. Mice (PBS n=3 day 7, n=4 day 10; MVA35Δ 
n=4; MVA n=4) were infected i.m. with MVA or MVA35Δ virus, and blood was collected on 
various days pi. Total VACV-Ig was measured by ELISA on VACV coated plates for day 7 and 
10.  Data show the average absorbance at 405 nm (+/- SEM).   
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Figure 34: VACV-specific antibody isotype response.  Mice (n=3-5) were infected i.m. with 
MVA or MVA35Δ virus, and blood was collected on various days pi. VACV-specific IgM, IgG, 
IgG1, and IgG2a were measured by ELISA on VACV coated plates for day 7 and 10.  Data show 
the average absorbance at 405 nm (+/- SEM).   
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Figure 35: VACV-specific IFNγ-producing cells.  a) IFNγ production.  On days 6 and 10 pi 
(i.m.), the spleens from 5 mice/group were harvested and splenocytes were analyzed by 
ELISPOT for virus-specific IFNγ production 48 h after stimulation with VACV-WR virus.  b) 
CD8+ cells.  On days 7 and 10 pi, spleens from vaccinated mice were analyzed by flow 
cytometry for the percentage of CD8+ T cells.  Data show the average (+/- SEM). 
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Figure 36: Cellular subsets in spleens.  On day 6 pi, spleens from MVA and MVA35Δ-infected 
mice (n=5) were stained for various cell surface markers to enumerate percentage of different 
cell types.  Data show average percentage (+/- SEM).  Gran, granulocytes; NK, natural killer; 
MO, macrophage; DC, dendritic cell. 
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Figure 37: Protection from lethal challenge.  Mice (n=5) were vaccinated i.m. on day with 107 
pfu of MVA or MVA35Δ virus, or mock-vaccinated with PBS.  Four weeks later, the mice were 
challenged i.n. with LD50 x 500 virulent WR virus.  Data show average percent change in pre-
challenge weight (+/- SEM).  All mice died in the PBS mock vaccinated group. 
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CHAPTER 6: DISCUSSION 
 
VACV encodes numerous proteins that function to evade the immune system, including 
inhibitors of apoptosis and soluble homologs of various cytokine receptors.  We expand the 
repertoire of known poxviral immune evasion tactics and show that infection of APC with 
VACV significantly reduced MHC class II antigen presentation (163), resulting in the decreased 
synthesis of 13 chemokines and cytokines. We show that VACV specifically exerts its effects on 
the APC, rather than on the responding T cell (163).  VACV significantly decreased antigen-
independent NO production from PEC and RAW macrophages, induced apoptosis of the PEC, 
significantly decreased the amount of a model peptide displayed in the cleft of the MHC class II 
molecule and mildly reduced MHC class II surface expression on PEC and 1153 B cells (163).  
Interestingly, VACV decreased MHC class II expression on the 1153 B cells, but did not induce 
apoptosis of these cells (163).  This indicates that VACV affects B lymphocytes differently than 
other APCs and that the reduction in MHC class II expression and antigen presentation is not 
always apoptosis dependent, as had been previously suggested (95). Our data suggests that the 
key mechanism of VACV inhibition of antigen presentation is its reduction of antigenic peptide 
loaded into the cleft of MHC class II molecules (163), which is consistent with data from the 
Blum laboratory showing that VACV decreases the amount of GAD peptide associated with 
MHC class II molecules in a human B cell line (116).   
While many VACV immunomodulatory proteins have been identified and characterized, 
nearly 25 highly conserved genes remain uncharacterized (213).  The poxvirus A35 protein was 
initially characterized by our laboratory in 2006 (170).  This protein is highly conserved in 
mammalian-tropic poxviruses, but has no sequence similarity to any other known protein, 
suggesting an important and novel function.  The initial characterization indicated that A35 was 
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not required for replication in eight cell lines, but was required for virulence when delivered i.n. 
in the mouse model (170).  Here we demonstrate that the A35 protein is also important for 
virulence when delivered i.p., bypassing the respiratory system (164).  In the i.n. mouse model, 
our data here, together with our previous data (170), show that 106 pfu of A35Δ-mutant virus is 
required to reach the same level of weight loss caused by 103 pfu of WR virus, a 1000-fold 
difference (164).  It was therefore important to determine the function of A35.  We hypothesized 
that the protein promoted virulence by either affecting viral replication in certain cell 
types/tissues or by regulating the host immune response.  Thus far, A35 has been found to not be 
necessary for replication in various cell lines and primary cells from six different mammalian 
hosts (162).  Furthermore, A35 is not required for the replication of the virus in the murine host 
organs and tissues early after infection (days 1-3) before the development of specific immunity 
(164).  Therefore we explored the effects of A35 on specific immunity.      
To study the effects of A35 on the adaptive immune response, we used a model in vitro 
MHC class II-restricted antigen presentation assay and report that A35 significantly decreased 
the amount of IL-2 and NO that was produced by the T cells and the macrophages, respectively, 
as well as 13 other cytokines/chemokines (162).  Further data showed that A35 did not have any 
significant effect on the T cells used in the assays, implicating the APC as the target of the 
protein (162).  A35Δ virus was able to infect the PEC as efficiently as WR, and A35 did not 
induce apoptosis of these cells (162).  A35 did not reduce antigen-independent NO production, 
indicating that A35 regulated aspects of the APC-T cell interaction.  A35 localized to the 
endosomes of the APC, modestly reduced MHC class II and B7.2 surface expression on the APC 
and significantly decreased the amount of peptide that was associated with MHC class II 
molecules (162) (Figure 38).  Whether these minor decreases in MHC class II antigen 
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presentation will have in vivo significance is unknown, but it is known that both CD4 and MHC 
class II are needed for full protection from disease and for the generation of protective antibody 
(224), while an absence of CD8 or MHC class I did not reduce protection (221, 224).   
VACV has been reported to decrease MHC class II antigen presentation in several model 
systems.  Deng et al reported a decrease in the presentation of KLH peptide by primary 
Langerhans cells to cognate CD4+ T cells following VACV infection (51).  Mann et al found 
that VACV infection decreased MHC class II mediated antigen presentation using primary 
macrophages as APC (126), and the Blum laboratory has reported a decrease in MHC class II 
antigen presentation using both professional and non-professional APC presenting numerous 
peptides (116).  Decreases in MHC class II antigen presentation, concomitant with a decrease in 
MHC class II surface expression, has also been observed in in vivo infected murine splenic 
dendritic cells (227).  Collectively, there is a growing amount of evidence to indicate that VACV 
perturbs peptide antigen presentation; however, no gene had been previously identified as 
contributing to this effect.  We report here that A35 decreases the association of peptide with 
MHC class II molecules, while increasing the number of CLIP-MHC class II complexes on the 
cell surface (162) (Figure 38).  This suggests that A35 may interfere with the processing and/or 
presentation of a wide variety MHC class II peptides.  This is the first report to identify a specific 
VACV gene product, A35, as contributing to the inhibition of peptide antigen presentation (162).  
Since A35 is highly conserved in all sequenced mammalian tropic poxviruses (170), it may have 
a similar function in many different poxviruses that infect different host species.   
Since MHC class II antigen presentation to CD4+ T cells is the seminal initiating event of 
the specific immune response, and both CD4 and MHC class II are important in the generation of 
a protective immune response in vivo (221, 224), we hypothesized that A35 would also decrease 
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the downstream effectors resulting from this event, including the generation of antigen-specific 
antibody-producing B cells, IFNγ-secreting T cells, and cytolytic T cells.  After infection of mice 
with a low dose of virus, we have shown that, compared to WR infected mice, A35Δ infected 
mice had larger spleens (suggesting a robust immune response), increased antigen-specific 
antibody production, increased IFNγ secreting T cells, and increased CTL killing (164).  The 
enhanced immunogenicity of the A35Δ virus correlated with decreased viral replication in target 
organs (days 6-9 post infection) (164).  Importantly, both A35Δ mutant virus and WR could 
replicate similarly in the organs of the mouse on days 1-3 post infection (164), which is before an 
adaptive immune response has been generated (36).  Thus, the decrease in viral replication seen 
in the A35Δ infected mice correlated with the development of the specific immune response.  
The increased immunogenicity of the A35Δ virus compared to WR was evident up to 34 days 
post infection, despite the presence of an increased antigen load following WR infection (164).  
Together, our data indicate that A35 is decreasing MHC class II antigen presentation to CD4+ T 
cells, which would result in smaller spleen size as a result of decreased lymphocyte proliferation 
or migration of immune cells to this organ, leading to a decrease in specific immunity including 
antibody production, IFNγ secretion, and CTL killing, all of which are important for protection 
from poxviruses (14, 32, 151, 224).   
Since the A35Δ virus is 1000 times safer (164, 170) and is more immunogenic than WR 
virus (164), we hypothesized that it would be a superior vaccine choice.  Impressively, the A35Δ 
virus was able to protect mice as well as WR from a lethal challenge of up to 1000 x LD50, even 
when given at a low dose (500 pfu/mouse) (164).  To be effective, vaccine strains need to retain 
the genes that encode proteins with protective B and T cell epitopes.  Several studies have not 
detected A35 as having B or T cells epitopes (48, 88), but a recent study has shown that epitopes 
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derived from A35 can bind certain MHC class I alleles (89).  Our data indicate that A35 deletion 
mutant vaccines would be superior to wild type strains, providing vastly increased safety coupled 
with improved immunogenicity and effective protection.     
We performed similar replication and immune response experiments using the attenuated 
vaccine strain MVA.  MVA was created by serial passage of wild-type VACV in CEFs.  This 
resulted in the deletion of nearly 25 kb of genetic material (136) and a highly attenuated virus.  
While A35 was not found to be required for replication in WR, it was possible that its loss was 
being compensated for by another redundant VACV gene.  Since MVA is missing a significant 
portion of the genome (136), we hypothesized that a replication function for A35 might be 
uncovered using this virus strain.  However A35 was not required for MVA replication in BHK-
21 cells, although it remains a possibility that A35 may be required for the replication of the 
virus in CEFs, the cells used during its attenuation.   
MVA is being used as a safer alternative to the traditional replicating vaccine and also as 
a platform vaccine for other infectious diseases and cancer, although its immunogenicity and 
efficacy are of concern.  MVA is unable to elicit the same levels of antibody and IFNγ secreting 
cells as the traditional replicating vaccine, even when given at 10-100 times the dose (14, 67, 
221).  The immunogenicity of MVA is of concern especially in persons with a weakened 
immune system due to HIV infection, organ transplantation, or cancer.  It is therefore important 
to find strategies that can increase the immunogenicity of MVA.  One way to do this is to create 
an MVA vaccine strain that is missing immunosuppressive genes.  Indeed, infection of mice with 
a mutant MVA virus lacking the gene for the soluble IL-1β receptor resulted in improved 
immunogenicity compared to the parental MVA (196).  Since removal of A35 from WR 
enhanced the immune response to infection (164), we hypothesized that its removal from MVA 
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may have a similar effect.  In WR, it was possible that A35 required an interacting viral protein 
to be functional.  Since MVA is missing nearly 25 kb of the VACV genome (136), it was 
possible that a protein that interacted with A35 had been deleted, rendering A35 ineffective.  
However, our data show that A35 still functions as an immunosuppressive gene in MVA, 
decreasing virus-specific antibody production, isotype switching, and IFNγ-secreting T cells.   
Thus, the removal of A35 from current vaccine strains will be beneficial by increasing their 
immunogenicity.   
 We have identified a new poxvirus virulence mechanism, the evolution of the A35 gene 
to block MHC class II antigen presentation.  This is an important contribution to the repertoire of 
viral immune evasion mechanisms.  This finding also has several important implications in 
human medicine.  VACV is an effective vaccine against poxvirus infection, but its virulence 
results in a high rate of vaccine-related complications.  It is therefore of importance to identify 
poxvirus virulence mechanisms in an effort to develop safer vaccines.  The data presented herein 
strongly support the removal of A35 from poxvirus and poxvirus-based vaccines, such as MVA.  
A35 deletion mutant vaccines are 1000 times safer, more immunogenic than wild type strains, 
and offer protection from disease (164).   
   Besides contributing to the development of safer, more immunogenic poxvirus-based 
vaccines, our data are also applicable to the development of anti-poxvirus therapies.  Post-
exposure vaccination has been shown to be effective at preventing disease, with effectiveness 
decreasing as time between exposure and vaccination increases (130).  Since the immune 
response to the A35Δ virus has improved kinetics compared to WR virus, we predict that A35Δ 
poxvirus vaccines would provide better protection from disease if given after exposure to the 
virus, even after the time when vaccination with the wild-type vaccine would be ineffective.  
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A35 would also be a good anti-poxvirus drug target.  Since it is not required for replication in 
tissue culture, it would be difficult for drug-resistant virus strains to be produced.   
Collectively, the data presented describe a novel poxvirus immuomodulatory mechanism 
and expand our knowledge of the arsenal of VACV immune evasion tactics.  An effective 
immune response will result in the clearance of virus from the infected host.  Our data indicate 
that the presence of A35 impedes initiation of the adaptive immune response (164).  This 
decrease allows the virus to establish itself throughout the host, resulting in sickness and death.  
Several questions regarding the mechanism of A35 remain.  It will be important to determine 
whether splenocytes from A35Δ-infected mice are better at presenting antigen to cognate CD4+ 
T cells compared to splenocytes from WR-infected mice, and if this inhibition occurs, the 
mechanism by which it occurs.  It has been reported that VACV can decrease MHC class II-
restricted antigen presentation using in vivo-infected splenic dendritic cells as APC (227), but no 
protein was identified as contributing to the effect.  It will also be important to determine with 
which cellular proteins A35 interacts.  Several proteins are important in facilitating the exchange 
of the remnant chaperone protein CLIP with antigenic peptide, including DM (Figure 38).  A35 
could also interact with the CLIP peptide itself or with the invariant chain (Ii) (Figure 38).  In 
preliminary microarray data, A35 did decrease the synthesis of both Ii and DM mRNA (data not 
shown).  Furthermore, our data show that there is a population of cells in the spleen that is 
resistant to VACV and A35 (162).  Indeed, other laboratories have shown that different cell 
types have different sensitivities to VACV infection (30, 175).  It will be important to also 
determine how A35 affects immunity in other organs, such as the lungs.  While some questions 
remain, it is clear that A35 is an important poxvirus immune evasion protein and its removal will 
increase both the immunogenicity and safety of poxvirus and poxvirus-based vaccines.   
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Figure 38: Model of A35 within the APC.  A35 (shown by the yellow star) localizes to the 
endosomes within APC.  It does not partition to a distinct endosomal compartment, but rather 
localizes throughout the range of endosomes.  Data indicate that A35 reduces the surface 
expression of a model peptide within the cleft of MHC class II in a subset of cells within the 
splenocyte population, while increasing the expression of surface CLIP.  The mechanism of how 
A35 does this is currently under investigation.  It is not known whether A35 is outside of the 
endosome or inside.  It is also not known with which cellular proteins A35 may interact.  The 
chaperone protein DM, which is directly involved in the exchange of CLIP for antigenic peptide, 
is a likely candidate.  A35 may also interact with MHC class II itself, or with the chaperone 
protein Ii.     
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